LASER TREATMENT OF SCARS IN DARK SKIN AND WARTS

Ph.D. dissertation

Department of Dermatology and Allergology

Albert Szent-Györgyi Medical Center

University of Szeged

2011

Szeged, Hungary

LASER TREATMENT OF SCARS IN DARK SKIN AND WARTS

Ph.D. dissertation

Ashraf Mohamed Abdel Magid Badawi

M.B.B.Ch, M.Sc. (Dermatology and Andrology)
Lecturer of Dermatology

Supervisor:

Lajos Kemény M.D., Ph.D., D.Sc.

Department of Dermatology and Allergology
Albert Szent-Györgyi Medical Center
University of Szeged

2011

Szeged, Hungary

Table of Contents

LIST OF PUBLICATIONS

Publications related to the subject of the dissertation

1. Badawi A, Tome MA, MD, Ayse N Turley AN, Kemeny L: Successful treatment of post chickenpox scars with microdermabrasion and sub-millisecond Nd:YAG (1064 nm) laser. Cosmetic Dermatology

2. Badawi A, Tome MA, Atteya A, Sami N, Morsy IA: Retrospective analysis of non-ablative scar treatment in dark skin types using the sub-millisecond Nd:YAG 1,064 nm laser. Lasers Surg Med. 2011;43:130-6. **IF: 2,605**

3. Badawi A, Shokeir HA, Salem AM, Soliman M, Fawzy S, Samy N, Salah M: Treatment of genital warts in males by pulsed dye laser. J Cosmet Laser Ther. 2006;8:92-5.

4. Samy N, Salah M, Soliman M, Badawi A: Plane warts can be managed successfully using long pulsed Nd-YAG laser. Kosmetische Medizin 2008;1:14-8.

Publications indirectly related to the subject of the dissertation

1. Badawi A, Soliman M, Sobhi R, Fawzy S, Shokeir H, Salem AM: Microdermabrasion in Cosmetic Dermatology: A Clinical Study. Cosmetic Dermatology. 2006;19:191-6.

2. Sami NA, Attia AT, Badawi A: Phototherapy in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7:627-32.

3. Salem AM, Shokeir H, Badawi A, ElMorsy I: Effective Reduction of Fine and Coarse Hair in Patients with Skin Types III-V by Long-Pulsed Alexandrite Laser at 5- & 20-Millisecond Pulse Durations. Cosmetic Dermatology Vol. 2003;16:39-42.

1. LIST OF ABBREVIATIONS

CO_2: Carbon dioxide

Er:YAG: Erbium:yttrium-aluminum-garnet

Er:YSGG: Erbium:yttrium-scandium-galium-garnet

PIH: Post inflammatory Hyperpigmentation

Nd:YAG: Neodymium:yttrium-aluminum-garnet

Hz: Hertz

PDL: Pulsed Dye Laser

MDA: Microdermabrasion

STDs: Sexually transmitted diseases

Msec: Millisecond

n: Number of cases

µs: Micro second

J/cm^2: Joul per centimeter square

mm: Millimiter

SPF: Sun Protective Factor

2. INTRODUCTION

2.1. BACKGROUND

2.1.1. Laser treatment of scars

The use of lasers to treat atrophic scarring conditions in darker skin types presents a significant challenge to laser practitioners.

Treatment options are limited due to increased risks of pigmentary complications including hypo- and hyper-pigmentation. This is especially true when attempting to treat large areas with atrophic scarring.

Post chickenpox scars are usually more common in adults and its treatment represents a major challenge for cosmetic dermatologists.

Current methods of treating scarring include traditional fully ablative erbium and carbon dioxide (CO_2) treatments as well as non-ablative and ablative fractional resurfacing with CO_2, erbium:yttrium-aluminum-garnet (Er:YAG), and erbium:yttrium-scandium-galium-garnet (Er:YSGG) lasers [1-8]. These options can be challenging for skin type IV patients and not feasible for patients with skin types V and VI without significant pre- and post-treatment skin conditioning and a hyper-pigmentation risk. With traditional fully ablative CO_2 resurfacing, studies showed hyper-pigmentation rates of 20% to 30% in Fitzpatrick skin type III and nearly 100% in skin type IV if treatment is performed without pre-treatment prophylaxis [9-11]. Further, 19% of traditional resurfacing patients experience some form of hypo-pigmentation. A recent study on the treatment of acne scarring with fractionated Er:YAG laser reported a Post inflammatory Hyperpigmentation (PIH) incidence of 50% in 15 subjects with skin types IV-VI [12].

When the 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser with the option of sub-millisecond pulse width is used with 300-500 micro second pulse durations, a 5 mm spot size and repetition rates of 5-10 Hz, it offers the ability to focus heat in the papillary and upper reticular dermis. The sub-millisecond 1064 nm Nd:YAG laser has been proven to stimulate new collagen synthesis [13]. It is therefore feasible that deliberate sub-millisecond 1064 nm Nd:YAG laser treatments could result in substantial reduction in scarring by stimulating collagen formation resulting in smoothing of the skin. [14-19]

2.1.2. Laser treatment of warts

Warts are benign epithelial neoplasm of the skin and mucosa resulting from human papilloma virus infection. They are a common dermatologic complaint, with an estimated incidence of 10% in children and young adults.

Verruca plana (flat warts) are less exophytic than common warts, frequently presenting as several or dozen of subtle papules 2-6 mm in diameter elevated above the surface less than a millimetre or so. These can be quite subtle, and may be missed by a casual observer. Pigmentary disturbances may be the most disturbing part of the flat wart infection to the patient. These lesions are frequently a problem on the face and the glabrous skin of non-immunocompromised individuals. At present, therapies aim to remove the lesion rather than specifically target human papillomavirus infection [14-19].

The four morphologic types of genital warts are condylomata acuminata, which have a cauliflowerlike appearance; papular warts, which are fleshcolored, dome-shaped papules, usually 1–4 mm in diameter; keratotic warts, which have a thick, crust-like layer and may

resemble common skin warts or seborrheic keratosis; and flat-topped papules, which appear macular to slightly raised.

In general, condylomata are most frequently detected on moist, partially keratinized epithelium, papular and keratotic warts on fully keratinized epithelium, and flat papular warts on either partially or fully keratinized epithelium [20-22].

Treatment of warts can be difficult, with most approaches relying on physical destruction of infected keratinocytes.

Common therapeutic approaches include liquid nitrogen, cryotherapy, topically applied acids, electro surgery, cantharidin application, bleomycin injection.

Genital wart therapies are classified as patient-applied or provider-administered.

Patient-applied treatments include podofilox solution and gel, and imiquimod cream [23,24].

To self-treat, patients must be able to identify and reach the warts and to follow the treatment application instructions. The provider-administered treatments include topical treatments (cryotherapy, podophyllin resin, trichloroacetic acid, bichloroacetic acid, and external application and intraurethral instillation of bacillus Calmette–Guerin); excisional treatments (curettage, electrosurgery, scissors excision, , cryosurgery and laser therapy); or injectable treatments (interferon or 5-fluorouracil/epinephrine gel implant) [25–33].

Many types of lasers have been used for the management of warts. Carbon dioxyde laser vaporization for infected tissue was used [29].

Tuncel et al. [33] used the pulsed dye laser (PDL) for treatment of perianal warts in children. They found the pulsed dye laser to be effective and less traumatic compared with other treatment options.

To date, there have been no trial evaluating the efficacy of long pulsed Nd-YAG laser in the treatment of common warts.

2.2. Aims

The primary objective of our retrospective study was to determine the safety and efficacy of the unique pulse modality of submillisecond to reduce the signs of atrophic scarring, texture and PIH secondary to the acne condition in darker skin types. The secondary objective is to assess the incidence of PIH resulting from the laser treatments.

As the post chickenpox scars are representing a clinical and therapeutic challange specially in dark skin so we also wanted to evaluate the safety and efficacy of using Microdermabrasion (MDA) and the sub-millisecond 1064 nm Nd:YAG laser in facial chickenpox scarring cases in adult men with skin type IV and V.

Our further aim was to determine the safety and efficacy of the flashlamp pumped pulsed dye laser for the treatment of uncomplicated genital warts in adult males and the safety and efficacy of Nd:YAG laser in treatment of plane warts.

3. PATIENTS AND METHODS

3.1. Treatments of scars
3.1.1. Scar treatment in dark skin

STUDY DESIGN AND METHODS:

This is a retrospective study evaluating the safety and efficacy of a sub-millisecond 1064 nm Nd:YAG laser. Treatments were conducted at the National Institute of Laser Enhanced Sciences, Dermatology Unit, at Cairo University, Egypt and at Saheroun Hospital, Khartoum, Sudan on 22 patients with Fitzpatrick skin types III ($n = 2$), IV ($n = 4$), V ($n = 14$), VI ($n = 2$) who had atrophic scarring such as acne scarring. All patients who were treated over a six month period between February and July of 2008 were included in the study.

Treatments were performed using 300-500 μs pulse duration, 14-16 J/cm^2 and 5-7 Hz repetition rate. The hand piece was held 1-2 cm off the surface of the skin (about the width of an index finger) during delivery. Treatments were performed without topical anesthesia. No prophylactic therapy was used before or after treatment to control PIH resulting from laser treatments. On average, each patient received 6 treatments (minimum 5, maximum 7). The average interval between treatments was 24.5 days with a range from 18.7 to 33.0 days. Follow-up photographs were taken, on average, 9 months (range of 3 to 10 months) after the final treatment. Patient ages ranged from 18-47 years with a mean of 28.6 years. The average number of pulses per procedure was 11,700 pulses ranging from 8,000 to 13,900 pulses. The patient to patient variation in the number of pulses was associated with the size of the surface area treated, not with the treatment indication. Treatment parameters used on each patient are listed in Table 1.

9

Table 1. Treatment Parameters and Follow-up Times

Patient	Age	# of Pulses per Treatment	# of Treatments	# of Days Between Treatments	Follow-up Post Final Treatment (months)
1	25	10,000	6	20.2	9
2	22	11,500	5	21	3
3	36	12,400	7	22.5	9
4	26	11,800	7	31	9
5	29	13,400	7	23	8
6	42	10,000	5	24.2	9
7	24	10,400	7	23.2	8
8	27	12,000	7	26.8	9
9	22	13,700	6	18.7	10
10	29	11,800	6	22	10
11	23	12,000	6	23.1	9
12	40	10,200	5	29	10
13	28	15,000	6	22.6	9
14	18	12,500	6	20.6	9
15	21	12,000	6	22.2	10
16	25	13,800	7	27.3	9
17	30	13,900	5	21.7	9
18	26	8,600	6	28.6	9
19	31	9,700	5	21	10
20	27	12,400	5	26.7	10
21	32	12,300	6	30.7	9
22	47	8,000	6	33	9
AVERAGE	**28.64**	**11,700**	**6**	**24.5**	**9**

To optimize laser results, the skin was treated with microdermabrasion (MDA) throughout the sub-millisecond 1064 nm Nd:YAG laser treatment series. Ten sessions of MDA were administered with an interval of 7 to 10 days between each session. A minimum of 3 days was allowed between MDA and laser treatments.

Following the MDA treatment, the whole face was treated with the sub-millisecond 1064 nm Nd:YAG laser. No additional passes were applied on the areas of atrophic scarring. The hand piece was held 1-2 cm off the face with continuous motion to build heat and erythema in the treatment area prior to moving to an adjacent part of the face. The surface area for each

treatment region was approximately 5 cm x 5 cm. The total and average number of pulses per treatment, and the total number of treatments per patient are also shown in Table 1.

Three independent physician reviewers (two dermatologists and one plastic surgeon) were asked to identify the before and after treatment photos which were presented to the physicians for assessment in random order. After selecting the before and after image, reviewers were asked to rank the degree of improvement in scarring, texture and PIH using a four-point scale (0 = < 25%, 1 = 25-50%, 2 = 51-75%, 3 = 76-100%). Any indication which did not apply to a patient was marked as N/A. The median improvement score was calculated based on scores from all three reviewers. When the before photo was incorrectly selected as the after photo (1 case only), the negative value of the improvement score was used in calculating the median score taking into account the magnitude of deterioration as assessed by the reviewer. This was done instead of excluding this case to avoid any bias in the data analysis.

Patients were evaluated for erythema, edema, purpura, blistering, crusting, hypo- and hyper-pigmentation, and scarring. Patients were also asked if they observed any adverse reaction of the above or any other skin reaction they consider adverse between visits.

Statistical Analysis

Statistical analysis was performed using Minitab statistical package, version 15.1.20.0 (Minitab Inc., State College, Pennsylvania). For statistical testing, two-sided one-sample Wilcoxon signed rank test was used, and *P* values less than .05 were considered statistically significant. Additionally, the medians and spread of the data were displayed in box plot graph. Kappa agreement analysis [34,35] was performed to measure the inter-reviewer reliability of before and after photos assessments and the kappa coefficient was reported.

3.1.2. Post chickenpox scars treatment

Regarding the Post-chickenpox scar group, Fifteen male patients aged 35 to 48 years (mean, 42 years) with Fitzpatrick skin type IV and V presented with a history of chickenpox infection 3 months earlier which left numerous scars over the face and forehead (Figure 9 1a, 1c, and 2a). All patients reported the occurrence of skin lesions few days after the onset of the fever. This was followed by scab formation over the skin lesions which started to fall off within 10 days of the onset of their appearance which resulted in scars. Gentian violet lotion or topical antibiotic ointment was applied topically over the skin lesions and antibiotic was administered orally for 1 week. No other intervention had been administered before the patients presented to us. Exclusion criteria included any prior trial for treatment of the scars, any concomitant systemic disease, and any active skin infection.

Patients were referred to our clinic seeking treatment for their facial scars. Treatments were performed without topical anesthesia. No prophylactic therapy was used before or after treatment to control postinflammatory hyperpigmentation (PIH) resulting from laser treatments.

The treatment regimen was started with MDA utilizing aluminum oxide crystals, followed by the session with the sub-millisecond 1064-nm Nd:YAG laser. The MDA sessions were repeated every 7 days for 8 sessions and the laser session was repeated every 3-4 weeks for 5-6 sessions. A minimum of 3 days was allowed between MDA and laser treatments. Treatment was performed without topical anesthesia and no prophylactic therapy was administered before or after treatment to control post inflammatory hyperpigmentation (PIH) resulting from laser treatments. Treatment was performed over 6 months.

The following parameters used during laser treatments: 5-mm spot size, 14 J/cm2, and 0.4-millisecond pulse width with a repetition rate of 5 Hz. The face was divided into squares of 5 x 5 cm and laser pulses were delivered with a continuous motion. The hand piece was moved

12

to the adjacent treatment area when erythema developed. Erythema was seen after an average of 500 pulses per treatment square. The laser treatment was conducted with no pre- or post-cooling of the skin while defocusing the hand piece 1 to 2 cm above the skin using multiple passes of the treatment area.

The patients were followed up for a period ranging between 3 and 12 months after the last laser session. There was no downtime or any incidence of adverse effects such as pigmentary changes or scab formation after the procedure. The post treatment erythema persisted for 20 to 30 minutes immediately after each laser session and completely faded away afterwards. The patients were asked to utilize sun block with at least SPF 30 in between the sessions.

A questionnaire was administered to all participants 4 weeks after the last laser session regarding changes in scarring and skin texture as well as PIH. These 3 parameters were graded on a 4-point scale (2=marked improvement; 1=mild improvement; 0=no change; -1=worsening). The same questionnaire also was administered to the treating physicians to grade changes observed in each participant.

Photographs were taken before treatment and 3 months (or more) after the last laser session. Blinded assessments were performed by 3 independent physicians using before and after photographs (unlabeled) that were not arranged in chronologic order. Reviewers were asked to identify the before and after photographs and evaluate the degree of improvement or worsening observed in scarring, skin texture, and PIH using a 4-point scale (2=marked improvement; 1=mild improvement; 0=no change; -1=worsening). No statistical analysis was performed.

Adverse effects were evaluated immediately after each laser treatment and 2 and 4 weeks after each laser session.

3.2.   Treatment of warts
3.2.1.   Treatments of genital warts

General examination for the whole body, including the oral mucosa, was done for signs of sexually transmitted diseases (STDs) (for example, vesicles, ulcers, warts, mucous patches, lymph node enlargement).

Local genital examination was done while the patients were completely uncovered from the umbilicus down to the knee. The skin of the lower abdomen, penis, scrotum, perineum, perianal area, upper thighs, and the urethral meatus were inspected under good illumination for the presence of warts and other STDs. In all settings, patients with genital warts were examined and treated for other STDs. Whenever possible, their wives or current sexual partners were also offered examinations and treatments for macroscopically visible warts and other STDs. Examination of the anogenital warts was done and the following data were recorded: site, number, type, area, presence of complications such as ulcerations or bleeding. The wart area was estimated as follows: the two largest perpendicular diameters were measured, and the wart area was defined as the product of the two measurements.

Finally, a total of 174 adult males with 550 uncomplicated anogenital warts and with no history of topical or systemic therapy for warts during the last 2 months were included and treated by pulsed dye laser. A pulsed dye laser (585 nm, 450 s pulse duration; Cynosure, USA) was used with the following parameters: spot size 5–7 mm according to the size of the lesions, and fluence 9–10 J/cm2.

Overlapping pulses were done, up to three to four pulses, until the appearance of grayish discoloration of the lesions which was an end point for lesion coagulation.

Treatments were repeated every 2 weeks with a maximum of three sessions. Topical antibiotic ointments were prescribed between the sessions to be used for a period of 7–10 days following every session. The number of warts, and the area of warts at presentation and at the

end of treatment was recorded. Any adverse reactions were also recorded. Patients were followed-up for at least 4 months after the warts had cleared.

3.2.2. Treatments of plane warts

Fifty patients with a total of 326 verrucae were enrolled in the study over 8 months period. They were 23 males and 27 females, with a mean age of 26.5 (12-41) years old. All patients were complaining of flat warts mainly on the forehead, cheeks, chin, neck, arms and the dorsum of the hands. Inclusion criteria included no treatment of lesions within the past month, and no history of constitutional or iatrogenic immunosuppression. All patients gave informed consent.

The study was completed by 42 patients, which completion defined as clearance of all visible warts or a maximum of 3 treatment sessions on the same lesion.

Treatment sessions consisted of treatment with the long pulsed Nd-YAG laser (1064 nm, Coolglide, Cutera, RIT 220 Excl.) with 20-30 msec pulse duration and fluence between 95–110 J/cm2, with 5,7 mm spot size according to the size of the lesion, applying double or triple overlapping pulses. Our endpoint was light greyish discoloration of the lesion.

Following treatment, there was slight peri-lesional erythema. Very minimal heat sensation or sometimes slight burning pain was experienced especially in children. Topical anaesthetic cream of 5 % lidocaine and 3.5 % prilocaine was used only in cases of children or with patients of low pain threshold. Treatment sessions were carried every 2 weeks with a maximum of 3 sessions on the same lesion. All patients and health care providers wore protective eyewear and micropore laser masks. A smoke evacuator was used as a precaution against potential aerosolised viral particles. Photographs were obtained at the initial visit and at 3 months follow up after the last treatment session.

15

4. RESULTS

4.1.   Treatments of scars

4.1.1. Treatment of scars in dark skin types

Blinded Photo Assessments

Two reviewers correctly identified all photos (22/22). The third reviewer incorrectly labeled one pair of before and after images and was not able to identify another pair of photos due to insufficient image quality (20/22).   The reviewers were highly consistent (inter-reviewer reliability, kappa of 0.88) in identification of before and after photos (kappa coefficient: poor < 0.20, fair 0.21-0.40, moderate 0.41-0.60, good 0.61-0.80, and very good 0.81-1.00).

Of the sixty-six possible image reviews for each category (22 images each reviewed by 3 physicians), one was determined by one reviewer as insufficient quality to grade before and after. Additionally, 4 images were excluded from scarring analysis, 4 were excluded from texture analysis and 5 were excluded from pigment analysis. Images were excluded due to insufficient focus, color balance and or lighting.

The results of the blinded photo assessments indicated clinically and statistically median improvement of 2 in scarring, 2.3 in texture and 2 in PIH ($P < 0.001$). Figure 1 displays the median improvement scores and the variability of data for all three conditions (scale of 0-3).

Figure 1. Median improvement of 2 in scarring, 2.3 in texture and 2 in pigment based on blinded photo assessments by three reviewers. The box illustrates the 25th percentile to the 75th percentile with a line placed at the median (50% percentile). The bottom and top ends of whiskers show the minimum and maximum respectively.

Figures 2 to 8 display photos from seven different patients with follow-up times. Subject characteristics and treatment parameters used on a particular patient can be found in Table 1.

17

Figure 2. Nd-YAG laser treatment of scars. 1a: Patient
1 baseline, 1b: patient 1 9-months post final treatment (6 sessions).

Figure 3. Nd-YAG laser treatment of scars. 3a: Patient 3 baseline, 3b: patient 3 9-months
post final treatment (7 sessions).

Figure 4. Nd-YAG laser treatment of scars. 4a: Patient 4 baseline, 4b: patient 4 9-months post final treatment (7 sessions).


Figure 5. Nd-YAG laser treatment of scars. 13a: Patient 13 baseline, 13b: patient 13 9-months post final treatment (6 sessions).

Figure 6. Nd-YAG laser treatment of scars. 14a: Patient 14 baseline, 14b: patient 14 9-months post final treatment (6 sessions).


Figure 7. Nd-YAG laser treatment of scars. 15a: Patient 15 baseline, 15b: patient 15 10-months post final treatment (6 sessions).

Figure 8. Nd-YAG laser treatment of scars. 20a: Patient 20 baseline, 20b: patient 20 10-months post final treatment (5 sessions).

Figures 2 to 8. Patients' photos (1, 3, 4, 13, 14, 15, 20) at baseline and at follow-up visit after final treatment.

Transient mild edema and erythema were observed in all patients and resolved within 2 hours after treatment.

No transient or permanent complications such as blistering, crusting, purpura, scarring, transient or permanent hyper- or hypo-pigmentation were noted.

There was no single patient who reported any adverse effects during or after the treatment sessions till the end of the follow up period in this study.

4.1.2. Treatment of chickenpox scars

All 15 participants were included in the analysis. The mean length of follow-up after the final laser session was 9.1 months. Questionnaire results demonstrated marked improvement in scarring, skin texture, and PIH as observed by participant and physician evaluation (Figures 9

and 10). Results of the participant assessment revealed mean scores in scarring, skin texture, and PIH of 1.8, 1.9, and 1.8, respectively. Physician evaluation of improvement revealed mean scores of 1.9, 1.9, and 1.8, respectively (2=marked improvement; 1=mild improvement). Participant and physician evaluation did not reveal scores of no change or worsening for the 3 parameters.

For the blinded photographic assessments, all 3 reviewers correctly identified the chronology of 13 participant photographs (13/15). Of the 90 possible photograph reviews for each category (15 before and 15 after photographs reviewed by 3 physicians), 2 were determined by 1 reviewer as insufficient quality to judge before and after photographs. Additionally, 4 photographs were excluded from skin texture analysis and 5 were excluded from PIH analysis. Photographs were excluded due to insufficient focus, color balance, or lighting. The results of the blinded photographic assessments indicated clinically significant improvements in scarring, skin texture, and PIH, with mean scores (based on all 3 reviewers) of 1.9, 1.8, and 1.8, respectively (2=marked improvement; 1=mild improvement). None of the reviewers scored these parameters as no change or worsening.

Transient mild edema and erythema were observed in all participants and resolved within a maximum of 2 hours after treatment. No transient or permanent complications such as blistering, crusting, purpura, scarring, or transient or permanent hyperpigmentation or hypopigmentation were noted at 2 or 4 weeks. None of the participants reported any adverse effects during or after the treatment sessions through the end of the follow-up period.

1(a): Baseline

1(b): 10 months post-final treatment (5 sessions)

1(c): Baseline

1(d): 10 months post-final treatment (5 sessions)

1(e): Baseline

1(f): 10 months post-final treatment (5 sessions)

Figure 9. Case 1 at baseline (1a, 1c, 1e) and after 8 sessions of Microdermabrasion and 5 sessions of laser treatment (1b, 1d, 1f)

2(a): Baseline   **2(b): 3 months post-final treatment (5 sessions)**

2(c): Baseline   **2(d): 3 months post-final treatment (5 sessions)**
(Close-up)

Figure 10. Case 2 at baseline (2a, 2c) and after 8 sessions of microdermabrasion
and 5 sessions of laser treatment (2b, 2e)

4.2.   Treatments of warts

4.2.1. Treatments of genital warts

The mean age of patients included was 31.33 $\pm$ 4.7 years (range from 22 to 49). The mean
duration of lesions was 4.29 $\pm$ 3.15 months (range from 1 to 48).

The number of warts ranged from one to 14 per patient (average 3.82 + 4.33). Warts were
frequently present with more than one lesion on one anatomical site. Warts were also present
more frequently on different genital sites (104 patients, 59.78%) and on one genital site in 70

patients (40.22%). Among those latter patients, lesions were present on the penis in 39 (22.41%), on the scrotum in 11 (6.32%), on the urethral meatus in four (2.29%), and on the Peri-anal area in 16 (9.2%). The mean area of lesions was 26.9 mm^2 and the area varied from 6 mm^2 to 64 mm^2. With regard to the morphological type of warts detected, it was predominantly condylomatous in 129 patients, papular in 31, keratotic in nine, and flat-topped papules in five patients.

Complete clearance of 528 anogenital warts (96%) treated by pulsed dye laser occurred after one to three sessions. A few small warts of short duration occurring on one anatomical site cleared significantly after fewer sessions and resulted in earlier clearance. Patients with fewer than three and with an area less than 20 mm2 cleared most frequently after one session. Other factors such as a patient's age and the morphological type did not affect the treatment results. Overlapping pulses (three to four) revealed better clearance of warts than single and even double pulsing. Side effects were infrequent and transient, mostly in the form of mild pain at treatment and transient hypopigmentation after treatment. Patients were followed-up for at least 4 months (up to 9 months in some cases).

Complete resolution and healing of skin without scaring or texture changes were found in the majority of cases (Figure 11 and 12).

Lesion recurrence rate was 5%. Recurrence was defined as a new wart at the same site detected within the 4-month follow-up period after clearance of lesions.

Figure 11. Penile condylomata acuminate: before treatment

Figure 12. After treatment (three sessions).

4.2.2. Treatments of plane warts

Of the 50 patients initially enrolled, 42 patients with a total of 256 warts completed the study. The 8 patients who withdrew, were for reasons unrelated to treatment. In the evaluation of treatment response, complete response was defined as complete absence of clinically apparent warts without any textural changes such as fibrosis or scar formation. Partial response was defined as greater than 50% reduction in wart size or number.

Complete response was observed in 35 patients (83.3 %) (Figure 13-15), while partial response was observed in 7 patients (16.7 %). No case showed no response to the lesion treatment. The mean number of treatments to achieve complete response was 2.00, while the mean number of treatments to achieve partial response was 2.65. Postoperative complications such as transient post inflammatory hypopigmentation was observed only in 4 cases and only 1 case experienced transient post inflammatory hyperpigmentation and was given hydroquinone 4% cream. The recurrence of warts during follow up period was reported only in 2 cases. As regards patient satisfaction, ninety two percent of all patients even those who experienced partial response were satisfied with the treatment they were given.

A Before treatment	B Immediately after treatment	C After 2 laser treatments
	Patient 1	

A Before treatment	B Immediately after treatment	C After 2 laser treatments
	Patient 2	

A Before treatment	B Immediately after treatment	C After 2 laser treatments
	Patient 3	

Figure 13. Nd:YAG laser treatments of plane warts; A) Before treatment, B) Immediately after Nd:YAG laser treatment showing mild erythema and edema and C) After 2 laser treatments with complete clearance of the lesion without any textural changes or scaring.

5. DISCUSSION

5.1. Laser treatment of scars

Retrospective photographic analysis of 22 cases of scars in our study and 15 cases of post chickenpox scars indeed shows that sub-millisecond 1064 nm Nd:YAG laser may be a viable treatment modality capable of generating improvement in texture, scarring and PIH secondary to the acne condition in darker skin types. Blinded photo assessments by three independent physicians indicated that six treatments performed, on average, 24.5 days apart resulted in clinically and statistically significant improvement in atrophic scarring, texture and PIH in patients with skin types III-VI. High consistency between reviewers was observed in identifying before and after photos.

It is noteworthy to state that The non-invasive treatments with the sub-millisecond 1064 nm Nd:YAG laser: (1) Improved the existing PIH from acne scarring; (2) Did not induce additional PIH; (3) Did not require pre- or post-treatment agents to control PIH in dark skin patients; (4) Did not require anesthetic.

The percentage of subjects with skin types IV and V included in studies for the treatment of atrophic scarring are very limited compared to lighter skin types due to pigmentation concerns [1-3]. Even with the use of hydroquinone pre- and post-treatment, a recently published prospective study of 15 subjects with skin types IV-VI and acne scarring using Er:YAG laser showed a 50% rate of the PIH [12]. In the same study, the pain levels were reported to increase as the skin type went from IV to VI and as the number of passes went from 1 to 8.

One challenge faced in this retrospective study was not all patient photos had sufficient image quality. As a result, a couple of photos were excluded from the data analysis. The second challenge was the data only captured an overall percentage improvement without assessments

of severity and types of scars at baseline and follow-up. This was due to the lack of high resolution standardized photos. In future studies, high resolution photos of scarring (using macro lens settings without flash [7] or a three-dimensional optical profiling system) should be used for objective assessment of scar severity and type [6, 8]. Lastly, it would be beneficial to collect data on patient satisfaction in addition to physician assessments.

The theory behind combining MDA treatments with laser treatments was to reduce the thickness of the stratum corneum thereby allowing greater light penetration to the papillary dermis. Thus, MDA treatments performed before the laser treatments were mild in intensity to prevent discomfort or complications from deep dermal abrasions [36]. The conservative MDA settings used in this study were not considered effective to treat acne scarring and PIH and were unlikely to have had an effect on the observed improvement 37-39]. Nonetheless, randomized split face studies would be required to definitely determine whether MDA is necessary or has an additional benefit when used in combination with laser treatments.

In previous studies, the sub-millisecond 1064 nm Nd:YAG laser therapy has been shown to stimulate collagen [13] and to improve scar severity [40]. However, no assessment has been performed on secondary improvement to texture and pigment. We hypothesize that the sub-millisecond Nd:YAG laser works through two parallel actions to safely stimulate collagen and improve discoloration. The first mechanism involves discrete cellular damage caused by direct absorption in hemoglobin, melanin and water during each pulse and bulk heating from cumulative pulsing in a region. As a result, damage created through direct absorption and through sustained time at elevated temperature initiates a healing response, prompting collagen stimulation [41,42].

Nd:YAG is absorbed by melanin and hemoglobin and is subsequently used for vascular and hair reduction treatments. Pulse durations in these treatments are in the 10-100ms range,

roughly 30-300 times longer than the pulse durations used in this study. The short pulse durations used in sub-millisecond treatment does not change the characteristics of chromophore absorption. At these short pulse durations, the laser energy is heating fine structures during each pulse, thus more selectively targeting the microvasculature in the papillary dermis and melanocytes within the epidermis without actually damaging the epidermis or larger vessels in the dermis.

The second mechanism of action occurs through bulk heating. The laser uses a 5 mm spot pulsing at 5-10 Hz to deliver large amounts of energy in relatively short bursts to a finite area of tissue. Heat conducts to surrounding tissue over time to create bulk heating in each treatment. The degree of bulk heating is a function of total energy delivered per unit area per unit time. The goal during treatment is to deliver energy to an area of tissue faster than the body can extract the heat. For this reason, skin cooling is not desired during treatment. This bulk heating occurs gradually and non-selectively through heat conduction, so no structures are specifically targeted. This allows for safe treatment, even on type VI skin.

5.2.   Laser treatment of warts

Management of genital warts presents a problem of increasing magnitude to genitourinary medicine and Dermatology specialists.

Choice of treatment is guided by patient preference, with consideration given to the patient's age and ability to comply with moderately complicated directions, to the location and number of warts, and to the clinician's training. Many conventional lines of therapy are used, the aim of which is to destroy the infected tissue; however, none are consistently effective, making genital warts a therapeutic challenge.

Laser therapy had been used for the treatment of genital warts since the 1970s [43].

CO2, argon, Nd:YAG and Er:YAG lasers have been used, especially for refractory genital warts, giant condyloma acuminatum or Buschke–Lowenstein tumor, with variable degrees of safety and efficacy [44–48].

The pulsed dye laser was used initially for selective photothermolysis of vascular lesions, whereby the wavelength is selectively absorbed by the oxyhemoglobin, leading to destruction of the vascular component of the tissue. It was also used in the management of other non-vascular lesions, depending on the photothermal effect of laser on the cutaneous tissue $\pm$ its selective photothermolysis effect. The pulsed dye laser was used for the management of simple and recalcitrant verrucae vulgaris on different sites of the body using fluencies

ranging from 6 to 9 J/cm2 [49]. Other studies reported higher fluencies of 9.4 J/cm2 giving variable clearance rates [50].

Tuncel et al. [33] used the pulsed dye laser for the management of perianal warts in children with a fluence of 7.5 J/cm2. In our study, we used higher fluencies of 9–10 J/cm2, which ensured greater destruction of the vascular component of the lesions.

The overlapping pulses increased the photothermal effect of the laser radiation leading to coagulation of the lesions and immediate graying of the warty tissue. The technique was done as an outpatient procedure and did not require any infiltration anesthesia as in electrocautery or surgery, which is another advantage of the pulsed dye laser in the treatment of genital warts. It is safe in comparison to the toxicity of podophyllotoxins, which are continuously investigated in an attempt to increase efficacy and decrease toxicity [23]. In the light of results from our study, in which there was a significant number of patients presenting with multiple and/or large size 5 lesions, complete resolution and healing of skin without scaring or texture changes were found in the majority of cases. This is in contrast with what is usually found with other traditional treatments such as electrocautery, surgical excision, cryotherapy or CO2 laser.

Lesion clearance rate in our study was 96%, which is superior to that achieved by the more widely used treatment modalities (32–88%) [24,51]. Better results (smaller number of sessions and earlier clearance) were observed with lesions of short duration and in cases with a small number of warts occurring on one anatomical site. On the other hand, failure of treatment that occurred only in 4% of cases was observed in highly recalcitrant lesions with a large number of warts, which might be attributed to increased fibrosis and hyperkeratosis due to previous attempts of treatment. Lesion recurrence rate (5%) was also less than reported with other treatment modalities (8–22%) [25]. Post-treatment recurrence rates are not well defined in most studies because in most cases either too few subjects have been studied or follow-up protocols had not been standardized [51].

Common warts are hyperkeratotic papulonodules most often seen on the hand, arms and legs, but can seen anywhere on the glabrous skin. Common verrucae represent the most frequent clinical lesions produced by human papillomavirus [52]. Verruca plana (flat warts) are less exophytic than common warts, frequently presenting as several or dozen of subtle papules 2–6 mm in diameter elevated above the surface less than a millimetre or so. These can be quite subtle, and may be missed by a casual observer. Pigmentary disturbances may be the most disturbing part of the flat wart infection to the patient. These lesions are frequently a problem on the face and the glabrous skin of non-immunocompromised individuals. At present, therapies aim to remove the lesion rather than specifically target human papillomavirus infection. Many different types of therapy have been used in treatment of verrucae. Commonly used methods of physical destruction include: electrodessication, cryosurgery and laser therapy. Chemical destruction is induced with salicylic acid, cantharidin, among others. Chemotherapeutic agents include podophillin resin and 5-fluorouracil. More recently immunomodulators such as interferon, systemic retinoids have been used [53–55].

Many types of lasers have been used for the management of warts. Carbon dioxyde laser vaporization for infected tissue was used [56]. Results were not superior than the ordinary electrocautery which remove blindly the infected tissue as well and may sometimes lead to textural changes. Several investigators have demonstrated the efficacy of 585 nm pulsed dye laser in treating warts [57–62]. The mechanism of action may be a result of intense heating of dermal vessels with collateral damage of virally infected keratinocytes. This theory is based on the presence of dilated and congested vessels at the base of most of verrucae [63] and the mechanism of selective photothermolysis [64] that result in targeting of haemoglobin by pulsed dye laser. To our knowledge, one report used KTP laser at 532 nm wavelength for treatment of recalcitrant pigmented warts, through selective photothermolysis and propagation of photoacoustic waves [65].

Nd-YAG laser hyperthermia proved to be effective in treatment of resistant warts with significant clearance of the lesions and absence of viral particles [66], but it cannot be performed on very sensitive areas for example lesions on the face, neck or cheeks. Patients will not tolerate the procedure since it is done without anaesthesia and needs laser exposure time of 1-2 min in comparison to the pulsed lasers with micro and milliseconds pulse durations. Thus laser hyperthermia is not practical for large number of lesions.

The Nd-YAG laser is one of the most versatile and interesting lasers in dermatological laser medicine. Almost no other laser has such a wide spectrum of applications. Depending on wavelength (1064 nm) and mode (continuous, Q-switched, long pulsed), it is applied on benign pigmented, vascular lesions and permanent hair reduction [67, 68], due to the fact that 1064nm is absorbed by all the skin chromophores.

Reports using long pulsed Nd-YAG laser as an effective line of treatment for vascular lesions such as telengietasia and venous lakes [69], encouraged us to use this laser system for thermal

destruction of resistant flat warts. With its deeper penetration and lower absorption coefficient for melanin, there is less concern for collateral epidermal damage [70].

Unlike ablative treatment modalities, with long pulsed Nd-YAG laser therapy, no wound was created, especially if the lesions were on exposed parts of the body mostly head and neck as in our study, thus avoiding prolonged post operative pain, crusting, scarring or downtime.

Applying the pulsed mode of laser system, made the technique tolerable by the patients, most of whom returned to work or normal activities immediately postoperatively. There was no need for local infiltration anaesthesia (only topical anaesthetic cream was used for selected cases) was another advantage. The limited number of sessions up to three sessions in our protocol was to be comparable to other treatment modalities such as topical retinoids, chemical cautery also for the cost benefit wise. Most of the patients who experienced partial response was due to their large number of warty lesions, most of the lesions were not de novo, they were being treated before and lasted for more than six months. The risk of high incidence of post inflammatory hyperpigmentation is minimized by preferentially sparing epidermal pigment. The procedure proved to be acceptable and effective by the patients. Our results are comparable to pulsed dye laser treatment modalities which was another positive point, with an advantage over the pulsed dye laser of having no post laser purpura and no consumables such as dye kit.

6. SUMMARY AND NEW FINDINGS

Preliminary data collected in our retrospective study suggest that sub-millisecond 1064 nm Nd:YAG laser treatments are safe and effective for treating atrophic scarring in patients with darker skin types, delivering clinically and statistically significant results with reduced risk of pigment complications. This offers a new standard of care or first treatment option for patients with a high risk of pigmentary complications. Prospective studies with the sub-millisecond Nd:YAG laser alone are required to further assess treatment outcomes considering the effect of number treatments as well as to determine targeted treatment parameters for improved effects on scars of various severity and type. Further, randomized split face studies are needed to show the treatment effect and the incidence of PIH compared to non-treated and treated controls with alternative treatments.

A further study was conducted to evaluate the safety and efficacy of the combination of the MDA and the sub-millisecond 1064-nm Nd:YAG laser in treatment of the post chickenpox scars in dark skin patients and the result of our study poved our treatment protocol to be safe and effective treatment modality for the postchickenpox scarring and inflammation induced hyperpigmentation in all skin types.

In our study of genital warts in males, the pulsed dye laser has been found to be a safe, effective, and satisfactory treatment for genital warts. It is capable of selectively destroying warts without damaging the surrounding skin.

Regarding the plane warts, we concluded that Long Pulsed Nd-YAG laser can be added to the long list of traditional treatment of plane warts as an effective, safe and well tolerated method with minimal complications. We recommend the following inclusion criteria for long pulsed Nd-YAG laser treatment of plane warts: limited numbers of warty lesions, especially on very sensitive areas, lasted for less than six months with no previous attempt of treatment. In

Patients with previous criteria, long pulsed Nd-YAG laser would be significantly more costly effective than other treatment modalities.

7. ACKNOWLEDGEMENTS

8. REFERENCES

1. Alster TS, Tanzi EL, Lazarus M: The use of fractional laser photothermolysis for the treatment of atrophic scars. Dermatol Surg. 2007;33:295-9.

2. Chrastil B, Glaich AS, Goldberg LH, Friedman PM: Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. Dermatol Surg. 2008;34:1327-32.

3. Kim S, Cho KH: Clinical trial of dual treatment with an ablative fractional laser and a non-ablative laser for the treatment of acne scars in Asian patients. Dermatol Surg. 2009;35:1089-98.

4. Cho SB, Lee SJ, Kang JM, Kim YK, Chung WS, Oh SH: The efficacy and safety of 10,600-nm carbon dioxide fractional laser for acne scars in Asian patients. Dermatol Surg. 2009;35:1955-61.

5. Cho SB, Lee SJ, Cho S, Oh SH, Chung WS, Kang JM, Kim YK, Kim DH: Non-ablative 1550-nm erbium-glass and ablative 10 600-nm carbon dioxide fractional lasers for acne scars: a randomized split-face study with blinded response evaluation. J Eur Acad Dermatol Venereol. 2009;17:1-5.

6. Chapas AM, Brightman L, Sukal S, Hale E, Daniel D, Bernstein LJ, Geronemus RG: Successful treatment of acneiform scarring with CO2 ablative fractional resurfacing. Lasers Surg Med. 2008;40:381-6.

7. Deng H, Yuan D, Yan C, Lin X, Ding X: A 2940 nm fractional photothermolysis laser in the treatment of acne scarring: a pilot study in China. J Drugs Dermatol. 2009; 8:978-80.

8. Walgrave SE, Ortiz AE, MacFalls HT, Elkeeb L, Truitt AK, Tournas JA, Zelickson BD, Zachary CB: Evaluation of a novel fractional resurfacing device for treatment of acne scarring. Lasers Surg Med. 2009;41:122-7.

9. Dover J, Arndt K, Geronemus RG, Alora MB: Laser resurfacing. In: Illustrated Cutaneous & Aesthetic Laser Surgery. Stanford: Appleton & Lange. 2000;81-112.

10. Goldman MP, Weiss RA: Laser resurfacing with the UPCO2 + Er:YAG lasers. In: Advanced techniques in dermatologic surgery. New York: Taylor & Francis. 2006;219-39.

11. Fitzpatrick RE: Skin resurfacing with carbon dioxide and erbium lasers. In: Cutaneous Laser Surgery. St. Louis: Mosby. 1999;339-436.

12. Mahmoud BH, Srivastava D, Janiga JJ, Yang JJ, Lim HW, Ozog DM: Safety and efficacy of erbium-doped yttrium aluminum garnet fractionated laser for treatment

of acne scars in type IV to VI skin. Dermatol Surg. 2010;36:602-9.

13. Schmults CD, Phelps R, Goldberg DJ: Non-ablative facial remodeling erythema reduction and histologic evidence of new collagen formation using a 300-microsecond 1064-nm Nd:YAG laser. Arch Dermatol 2004;140:1373-76.

14. Cobb MW: Human papillomavirus infection. J Am Acad Dermatol 1990;22:547-66.

15. Bunney MH, Nolan MW, Williams DA: An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol 1976;94:667-79.

16. Gibbs RC, Scheiner AM: Long-term follow-up evaluation of patients with electrosurgically treated warts. Cutis 1978;21:383-4.

17. Shumer SM, O Keefe EJ: Bleomycin in the treatment of recalcitrant trant warts. J AM Acad Dermatol 1983;9:91-6.

18. Street ML, Roenigk RK: Recalcitrant periungual verrucae: the role of carbon dioxide laser vaporization. J Am Acad Dermatol 1990;23:115-20.

19. Lim JTE, Goh CL: Carbon dioxide laser treatment of periungual and subungual viral warts. Australas J Dermatol 1992;33:87-91.

20. Wikstrom A: Clinical and serological manifestations of genital human papillomavirus infection. Acta Derm Venereol Suppl (Stockh). 1995;193:10.

21. Rowson KEK, Mahy BWJ: Human papova (wart) virus. Bacteriol Rev. 1967;31:110.

22. Meisels A, Fotin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol. 1976;20:505.

23. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS: An open, comparative, study of the efficacy of 0.5% 6 podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminate in males and females. Int J STD AIDS. 1993;4:194.

24. Beutner KR, Ferenczy A: Therapeutic approaches to genital warts. Am J Med. 1997;102:28.

25. Von Krogh G: Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11:598.

26. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens LL, et al.: Imiquimod, a patientapplied immunoresponse modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789–94.

27. Bohle A, Doehn C, Kausch I, Jocham D: Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-

Guerin. J Urol. 1998;160:394.

28. Metawea BA, Elnashar AM, Ismail IK, Kasem W: Application of viable bacillus Calmette-Guerin topically as a primary treatment in condylomata acuminata. MSc Thesis. Cairo: Cairo University Press; 2002.

29. Gay C, Terzibachian JJ, Gabelle C, Reviron S, Ramanah R, Mougin C: Carbon dioxide laser vaporization of genital condyloma in pregnancy. Gynecol Obstet Fertil. 2003;31:214.

30. Mahmoud KZ, Mo'men MN, Mostafa T, Roaia MMF, Anis TH, Salem AM: Evaluation of the role of interferon alpha 2B in the treatment of condylomata acuminata. Egypt J Androl Reprod. 1993;7:81.

31. Condylomata International Collaborative Study Group: Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon a-2a in the treatment of anogenital condylomata acuminata. J Infect Dis. 1993;167:82.

32. Swinehart JM, Sperling M, Phillips S, Kraus S, Gordon S, McCarty JM, et al.: Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata: a phase III clinical study. Arch Dermatol. 1997;133:67.

33. Tuncel A, Gorgu M, Ayhan M, Deren O, Erdogan B: Treatment of anogenital warts by pulsed dye laser. Dermatol Surg. 2002;28:350.

34. Douglas GA: Some common problems in medical research. In: Practical statistics for medical research. Boca Raton: CRC Press LLC. 1999:403-9.

35. Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-363.

36. Karimipour DJ, Karimipour G, Orringer JS: Microdermabrasion: an evidence-based review. Plast Reconstr Surg. 2010;125:372-7. Review.

37. Tsai RY, Wang CN, Chan HL: Aluminum oxide crystal microdermabrasion: A new technique for treating facial scarring. Dermatol Surg. 1995;21:539-42.

38. Shim EK, Barnette D, Hughes K, Greenway HT: Microdermabrasion: a clinical and histopathologic study. Dermatol Surg. 2001;27:524-30.

39. Wang SQ, Counters JT, Flor ME, Zelickson BD: Treatment of inflammatory facial acne with the 1,450 nm diode laser alone versus microdermabrasion plus the 1,450 nm laser: a randomized, split-face trial. Dermatol Surg. 2006;32:249-55; discussion 255.

40. Lipper G, Perez M: Non-ablative acne scar reduction after a series of treatments with a short-pulsed 11,064-nm Neodymium:YAG laser. Dermatol Surg 2006;32:998-1006.

41. Trelles MA, Alvarez X, Martín-Vázquez MJ, Trelles O, Velez M, Levy JL, Allones I: Assessment of the efficacy of non-ablative long-pulsed 1064-nm Nd:YAG laser treatment of wrinkles compared at 2, 4, and 6 months. Facial Plast Surg. 2005;21:145-53.

42. Yeh AT, Kao B, Jung WG, Chen Z, Nelson JS, Tromberg BJ: Imaging wound healing using optical coherence tomography and multiphoton microscopy in an in vitro skin-equivalent tissue model. J Biomed Opt. 2004;9:248-53.

43. Vainberg ZS, Vishnevskii AA, Likhter MS: Use of lasers for surgical treatment of urethral polyps and condylomata acuminata of the penis. Urol Nefrol. 1977;2:44.

44. Fuselier HA Jr, McBurney EI, Brannan W, Randrup ER: Treatment of condylomata acuminata with carbon dioxide laser. Urology 1980;153:265.

45. Patrice T, Dreno B, Jutel P, Cloarec D, Barriere H, Le Bodic L: The role of the argon laser in the treatment of condylomata acuminata of the anal margin and canal. Ann Gastroenterol Hepatol. 1985;5:283.

46. De la Campa MMA, Moreno RJA, Ochoa PJ: Treatment of giant vulvar condylomata acuminata combining CO2 laser and electrosurgery. Gynecol Obstet. 2003;68:27.

47. Zaak D, Hofstetter A, Frimberger D, Schneede P: Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology. 2003;5:1011.

48. Wollina U. Er: YAG laser followed by topical podophyllotoxin for hard to treat genital warts. J Cosmet Laser Ther. 2003;1:35.

49. Kenton-Smith J, Tan ST: Pulsed dye laser therapy for viral warts. Br J Plast Surg. 1999;52:554.

50. Ross BS, Levine VJ, Nehal K, Tes Y, Ashinoff R: Pulsed dye laser treatment of warts: an update. Dermatol Surg. 1999;25:377.

51. Koutsky LA, Kiviat NB: Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, et al., editors.: Sexually transmitted diseases. 3rd ed. Vol. 1. New York, St Louis, San Francisco, London, Paris, Tokyo, Toronto: McGraw-Hill Health Profession Division 1999;347-59.

52. Kilkenny M, Marks R: The descriptive epidemiology of warts in the community. Australas J Dermatol 1996;2:80-6.

53. Brodell RT, Bredle DL: The treatment of palmar and plantar warts using natural alpha interferon and needeless injector. Dermatol Surg 1995;21:213-8.

54. Beissert S, Koch U, Sunderkotter C, Luger TA, Schwarz T: Successful treatment

of diieminated verrucae vulgares with interferon beta. J Am Acad Dermatol 1993;29: 1041-2.

55. Yilmaz E, Alpsoy E, Basaran E: Cimetidine therapy for warts; a placebo-controlled, double-blind study. J Am Acad Dermatol 1996;34:1005-7.

56. Serour F, Somekh E: Successful treatment of recalcitrant warts. Eur J Pediatr Surg 2003;13:219-23.

57. Jain A, Storwick GS: Effectiveness of the 585nm flashlamp pulsed tunable dye laser (PTDL) for treatment of plantar verrucae. Lasers Surg Med 1997;21:500-5.

58. Ross BS, Levine VJ, Nehal K, Tse Y, Ashinoff R: Pulsed dye laser treatment of warts: an up date. Dermatol Surg 1999;5:377-80.

59. Vargas H, Hove CR, Dupree ML, William EF: The treatment of facial verrucae with pulsed dye laser. Laryngoscope 2002;9:1573-6.

60. Kopera D: Verrucae vulgares: flashlamp-pumped pulsed dye laser treatment in 134 patients. Int J Dermatol 2003;11:905-8.

61. Wu C, Langan S, Kilmurray M, Lawlor D, Watson R: Efficacy of pulsed dye laser for viral warts- an internal audit. Ir Med J 2003;3:80,82-3.

62. Komericki P, Akkilic M, Kopera D: Pulsed dye laser treatment of genital warts. Lasers Surg Med 2006;38:273-6.

63. Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, editors: Levers histopathology of the skin. 8th ed. Philadelphia: JB Lippincott 1997;578-82.

64. Anderson RR, Parrish JA: Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983;220:524-7.

65. Li Y, Yang: Treatment of recalcitrant-pigmented flat warts using frequency doubled Q-switched Nd-YAG laser. Lasers Surg Med 2001;29:244-7.

66. Alxander P, Talal A, Wolfgang B, Ulrich H, Michael L: Nd-YAG laser hyperthermia in the treatment of recalcitrant verrucae vulgares (Regensburgs technique). Acta Derm Venerol 1994;74:212-214.

67. Groot D, Rao J, Johnston P, Nakatsui T: Algorithm for using a long pulsed Nd-YAG laser in the treatment of deep cutaneous vascular lesions. Dermatol Surg 2003;29:35-42.

68. Dierickx C: Hair removal by lasers and intense pulsed light sources. Dermatologic Clinics 2002;20:135-146.

69. Bekhor PS: Long pulsed Nd-YAG laser treatment of venous lakes: report of series of 34 cases. Dermatol Surg 2006;32:151-4.

70. Divya R, Eric C, Nathan S, Uebelhoer D, Thomas E: Laser treatment of vascular lesions. Clinics in Dermatology 2006;24:8-15.

Appendix

Successful Treatment of Chickenpox Scars With Microdermabrasion and a Nonablative, Submillisecond, 1064-nm Nd:YAG Laser

Ashraf Badawi, MD; Mohamed A. Tome, MD; Ayse Turley, DDS, MPH; Lajos Kemeny, MD, PhD, DSc

The use of lasers in patients with darker skin types presents a remarkable challenge to laser practitioners, especially when treating large areas of atrophic scarring following chickenpox infection. Treatment options often are limited because of an increased risk for pigmentary complications, including hypopigmentation and hyperpigmentation. This retrospective study evaluated the efficacy of a nonablative, submillisecond, 1064-nm Nd:YAG laser used in combination with microdermabrasion (MDA) therapy over 6 months to treat facial chickenpox scarring in 15 males with Fitzpatrick skin type IV or V. Participants were treated at a fluence of 14 to 16 J/cm^2 and a pulse duration of 0.4 milliseconds with a repetition rate of 5 Hz. Five to 6 laser treatments were performed on each participant every 3 to 4 weeks and 8 MDA treatments were performed 7 to 10 days apart. The mean follow-up time was 9.1 months after the final treatment session (range, 3–12 months). Both the participants and the treating physicians were asked to complete a questionnaire regarding changes in scarring and skin texture as well as postinflammatory hyperpigmentation (PIH) using a 4-point scale (2=marked improvement; 1=mild improvement; 0=no change; −1=worsening). Blinded assessments were performed by 3 independent physicians using before and after photographs (unlabeled) that were not arranged in chronologic order. Reviewers were instructed to identify the before and after photographs and evaluate the degree of improvement

or worsening in scarring, skin texture, and PIH secondary to chickenpox infection. Clinically significant improvements in scarring, skin texture, and PIH were evaluated. Ultimately, data collected in this study suggest that a nonablative, submillisecond, 1064-nm Nd:YAG laser used in combination with MDA therapy is an effective treatment method for atrophic chickenpox scarring in patients with darker skin types, delivering clinically significant results with reduced risks for pigmentary complications and patient discomfort.

Cosmet Dermatol. 2011;24:389-394.

Chickenpox, also known as varicella, is a highly contagious disease caused by the varicella-zoster virus. The disease rapidly spreads through direct contact with secretions from chickenpox vesicles as well as through the air when an infected person coughs or sneezes. Varicella remains contagious until all pustules crust over, and it is possible for a person who has never had chickenpox or been immunized against it to become infected simply by being in the same room as someone with the disease.[1]

Symptoms typically appear 10 to 21 days following initial exposure to the varicella-zoster virus and tend to be worse in adults compared to children.[2] Early symptoms of chickenpox may include body aches, fever, fatigue, and irritability. A characteristic papular rash of up to 500 itchy blisters eventually appears over the entire body, usually lasting 5 to 7 days and healing as scabs. The rash also can spread to the mouth or other internal parts of the body.[2] Patients who previously received the varicella vaccine may sometimes develop symptoms on exposure, but the presentation usually is mild, with a rash of only 50 or fewer red papules that rarely become vesicles.[3,4] Although chickenpox usually is self-limited, it can cause more serious complications in immunocompromised patients (eg, young children; older adults; patients with AIDS, lupus, or leukemia) such as secondary skin infections, pneumonia, and encephalitis.[2] Secondary bacterial infection of skin lesions manifesting as impetigo, cellulitis, or erysipelas is the most common complication in healthy children, with staphylococci and streptococci being the most commonly implicated bacterial pathogens. Bacterial superinfection often is a predisposition for chickenpox scarring.[5-9]

Chickenpox scars usually are more common in adults and scar treatment often represents a major challenge for cosmetic dermatologists, especially when dealing with patients with darker skin types because of the higher risk for pigmentary complications. This retrospective study evaluated the efficacy of a nonablative, submillisecond, 1064-nm Nd:YAG laser used in combination with microdermabrasion (MDA) therapy over 6 months to treat facial chickenpox scarring in 15 males with Fitzpatrick skin type IV or V.

METHODS
Study Population
Patients presented to our clinic seeking treatment of facial chickenpox scars. The study included 15 males aged 35 to 48 years (mean, 42 years) with Fitzpatrick skin type IV or V who reported a history of chickenpox infection 3 months prior that resulted in numerous atrophic scars on the face and forehead. All participants reported the occurrence of skin lesions within 3 to 7 days of onset of fever, followed by scab formation that resulted in scarring within 10 days of initial appearance. Gentian violet lotion or topical antibiotic ointment was applied to the lesions and antibiotics were orally administered for 1 week. Participants received no other treatment prior to inclusion in the study. Exclusion criteria included any prior trial for treatment of the scars, any concomitant systemic disease or medications, and any active skin infection.

Treatment Regimen
Treatment began with MDA therapy utilizing aluminum oxide crystals, followed by nonablative, submillisecond, 1064-nm Nd:YAG laser therapy. Microdermabrasion treatments were repeated every 7 to 10 days for 8 sessions and laser treatments were repeated every 3 to 4 weeks for 5 to 6 sessions. Microdermabrasion and laser treatments were performed a minimum of 3 days apart. Treatment was performed without topical anesthesia and no prophylactic therapy was administered before or after treatment to control postinflammatory hyperpigmentation (PIH) resulting from laser treatments. Treatment was performed over 6 months.

The parameters for all laser treatments included a 5-mm spot size, fluences of 14 to 16 J/cm^2, and a pulse duration of 0.4 milliseconds with a repetition rate of 5 Hz. Treatment sites were divided into smaller areas measuring 5×5 cm. Laser pulses were delivered in a continuous motion while defocusing the handpiece 1 to 2 cm above the skin using multiple passes of the treatment area.

Participant Demographics[a]

Participant No.	Age, y	Fitzpatrick Skin Type	No. of MDA Sessions	No. of Laser Sessions	Follow-up Period, mo
1	45	V	8	5	10
2	43	IV	8	5	3
3	37	V	8	6	9
4	47	IV	8	6	8
5	36	V	8	6	12
6	42	V	8	6	10
7	41	IV	8	6	9
8	48	IV	8	6	9
9	35	IV	8	6	10
10	44	V	8	6	12
11	46	V	8	6	6
12	39	V	8	5	8
13	40	V	8	5	9
14	44	IV	8	6	10
15	43	IV	8	6	12

Abbreviation: MDA, microdermabrasion.
[a]The mean age was 42 years; mean number of MDA sessions was 8; mean number of laser sessions was 5.7; and mean follow-up period was 9.1 months.

The handpiece was moved to an adjacent treatment area when erythema developed in the targeted area, typically after an average of 500 pulses per treatment square. Each session was conducted without cooling the skin before or after laser treatment.

Participants were followed for 3 to 12 months after the final laser session. There was no downtime after the procedure. Participants also were instructed to utilize sunscreen with a sun protection factor of at least 30 in between sessions.

Evaluations

A questionnaire was administered to all participants 4 weeks after the last laser session regarding changes in scarring and skin texture as well as PIH. These 3 parameters were graded on a 4-point scale (2=marked

improvement; 1=mild improvement; 0=no change; −1=worsening). The same questionnaire also was administered to the treating physicians to grade changes observed in each participant.

Photographs were taken before treatment and 3 months (or more) after the last laser session. Blinded assessments were performed by 3 independent physicians using before and after photographs (unlabeled) that were not arranged in chronologic order. Reviewers were asked to identify the before and after photographs and evaluate the degree of improvement or worsening observed in scarring, skin texture, and PIH using a 4-point scale (2=marked improvement; 1=mild improvement; 0=no change; −1=worsening). No statistical analysis was performed.

Adverse effects were evaluated immediately after each laser treatment and 2 and 4 weeks after each laser session.

RESULTS

All 15 participants were included in the analysis (Table). The mean length of follow-up after the final laser session was 9.1 months. Questionnaire results demonstrated marked improvement in scarring, skin texture, and PIH as observed by participant and physician evaluation (Figures 1 and 2). Results of the participant assessment revealed mean scores in scarring, skin texture, and PIH of 1.8, 1.9, and 1.8, respectively. Physician evaluation of improvement revealed mean scores of 1.9, 1.9, and

Figure 1. Participant with chickenpox scarring at baseline (A and C) and following 5 sessions of laser treatments and 8 sessions of microdermabrasion (B and D).

Figure 2. Participant with chickenpox scarring at baseline (A) and following 5 sessions of laser treatments and 8 sessions of microdermabrasion (B).

1.8, respectively (2=marked improvement; 1=mild improvement). Participant and physician evaluation did not reveal scores of no change or worsening for the 3 parameters.

For the blinded photographic assessments, all 3 reviewers correctly identified the chronology of 13 participant photographs (13/15). Of the 90 possible photograph reviews for each category (15 before and 15 after photographs reviewed by 3 physicians), 2 were determined by 1 reviewer as insufficient quality to judge before and after photographs. Additionally, 4 photographs were excluded from skin texture analysis and 5 were excluded from PIH analysis. Photographs were excluded due to insufficient focus, color balance, and/or lighting. The results of the blinded photographic assessments indicated clinically significant improvements in scarring, skin texture, and PIH, with mean scores (based on all 3 reviewers) of 1.9, 1.8, and 1.8, respectively (2=marked improvement; 1=mild improvement). None of the reviewers scored these parameters as no change or worsening.

Transient mild edema and erythema were observed in all participants and resolved within a maximum of 2 hours after treatment. No transient or permanent complications such as blistering, crusting, purpura, scarring, or transient or permanent hyperpigmentation or hypopigmentation were noted at 2 or 4 weeks. None of the participants reported any adverse effects during or after the treatment sessions through the end of the follow-up period.

COMMENT

The use of lasers to treat atrophic scarring in darker skin types presents a remarkable challenge to laser practitioners. Current treatment modalities, including deep dermal peels, ablative and nonablative fractional laser resurfacing, and surgical techniques, are not widely available to patients with Fitzpatrick skin types IV to VI because of increased risks for pigmentary complications. These complications are particularly likely when treating large areas of facial scarring, including scars following chickenpox infection.

The procedure evaluated in this study combined MDA and laser therapy to optimize results of atrophic scar treatment in darker skin types. Microdermabrasion was included to improve the structure of the epidermis by

decreasing the population of keratinocytes and stimulating the proliferation of the living cell layer, microcirculation, and lymphatic drainage.[10-12] The laser treatments were intended to induce sustained volumetric heating by increasing the temperature of the dermis to approximately 40°C and maintaining it for a minimum of 2 minutes. The goal of the sustained volumetric heating of the dermis was to initiate a mild inflammatory reaction leading to the deposition of fibroblasts followed by the synthesis of new collagen in the treated area.[13-15]

Ultimately, data collected in this study suggest that a nonablative, submillisecond, 1064-nm Nd:YAG laser used in combination with MDA is an effective treatment method for atrophic chickenpox scarring in patients with darker skin types, delivering clinically significant results with reduced risks for pigmentary complications and patient discomfort.

It is noteworthy that existing PIH improved in all participants following the procedure; it also is clinically significant that the laser treatment did not induce additional PIH or require anesthetics or additional treatment agents before and after therapy sessions to control PIH. The treatment modality evaluated in this study may offer a new standard of care and first-line treatment option for patients with atrophic scarring and a high risk for pigmentary complications.

CONCLUSION
The combination of MDA therapy and nonablative, submillisecond, 1064-nm Nd:YAG laser treatment is an effective treatment modality for chickenpox scarring and PIH in darker skin types.

REFERENCES
1. Schwartz RA, Jordan MC, Rubenstein DJ. Bullous chickenpox. *J Am Acad Dermatol.* 1983;9:209-212.
2. Vinzio S, Lioure B, Goichot B. Varicella in immunocompromised patients. *Lancet.* 2006;368:2208.
3. Chartrand SA. Varicella vaccine. P*ediatr Clin North Am.* 2000;47:373-394.
4. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. *Pediatrics.* 2007;120: 221-231.
5. Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. *Clin Infect Dis.* 1996;23:698-705.
6. Higuchi S, Toichi E, Kore-eda S, et al. An adult case of Fournier's gangrene preceded by varicella. *Acta Dermatol Kyoto Engl Ed.* 1997;92:375-380.
7. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. *Ann Intern Med.* 2009;150:40-44.
8. Choo PW, Donahue JG, Manson JE, et al. The epidemiology of varicella and its complications. *J Infect Dis.* 1995;172: 706-712.
9. Papadopoulos AJ, Schwartz RA, Janniger CK. Chickenpox. *Cutis.* 2000;65:355-358.
10. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: an evidence-based review. *Plast Reconstr Surg.* 2010;125: 372-377.
11. Tsai RY, Wang CN, Chan HL. Aluminum oxide crystal microdermabrasion: a new technique for treating facial scarring. *Dermatol Surg.* 1995;21:539-542.
12. Shim EK, Barnette D, Hughes K, et al. Microdermabrasion: a clinical and histopathologic study. *Dermatol Surg.* 2001;27: 524-530.
13. Schmults CD, Phelps R, Goldberg DJ. Nonablative facial remodeling: erythema reduction and histologic evidence of new collagen formation using a 300-microsecond 1064-nm Nd:YAG laser. *Arch Dermatol.* 2004;140:1373-1376.
14. Lipper G, Perez M. Nonablative acne scar reduction after a series of treatments with a short-pulsed 1,064-nm neodymium:YAG laser. *Dermatol Surg.* 2006;32:998-1006.
15. Trelles MA, Alvarez X, Martín-Vázquez MJ, et al. Assessment of the efficacy of nonablative long-pulsed 1064-nm Nd:YAG laser treatment of wrinkles compared at 2, 4, and 6 months. *Facial Plast Surg.* 2005;21:145-153. ∎

Quick Poll Question
What laser would you use for acne scars?

○ A. CO_2 laser

○ B. Er:YAG laser

○ C. Fractional photothermolysis

○ D. Q-switched Nd:YAG laser

Go to **www.cosderm.com** to answer our Quick Poll Question

Retrospective Analysis of Non-Ablative Scar Treatment in Dark Skin Types Using the Sub-Millisecond Nd:YAG 1,064 nm Laser

Ashraf Badawi, MD,[1,2]* Mohamed A. Tome, MD,[3] Abeer Atteya, MD PhD,[2] Nevine Sami, MD PhD,[2] and Iman A.L. Morsy, MD[4]

[1]*Department of Dermatology and Allergology, Albert Szent-Gyorgyi Medical Center, University of Szeged, Hungary*
[2]*Dermatology Unit, National Institute of Laser Enhanced Sciences, Cairo University, Egypt*
[3]*Department of Dermatology, Faculty of Medicine, Al Rebat University, Khartoum, Sudan*
[4]*Department of Dermatology, Faculty of Medicine, Alexandria University, Egypt*

Background: The use of lasers to treat atrophic scarring conditions in darker skin types presents a significant challenge to laser practitioners. Current treatment modalities, including deep dermal peels; ablative; non-ablative; and fractional laser resurfacing and surgical techniques, are limited in skin types IV through VI due to increased risks of hyper- and hypo-pigmentation. This is especially true when attempting to treat large areas of acne scarring. This study investigates the treatment of atrophic scarring with a non-ablative sub-millisecond-pulsed 1,064 nm Nd:YAG laser in darker skin types.

Objective: To evaluate the safety and efficacy of a sub-millisecond 1,064 nm Nd:YAG laser for the treatment of atrophic scarring in Fitzpatrick skin types III–VI through retrospective photographic analysis.

Methods: A retrospective analysis was conducted of all patients ($n = 22$) who received sub-millisecond Nd:YAG laser treatments for atrophic scarring over a 6-month period. Patients had Fitzpatrick skin types III–VI and were treated for the indication of atrophic scarring using the fluence of 14–16 J/cm^2, pulse duration of 300–500 microseconds and repetition rate of 5–7 Hz. An average of six treatments was performed on each patient approximately 3 weeks apart and the mean follow-up time after the final treatment was 9 months (range of 3–10 months). Blinded photographic assessments were performed by three independent physicians using photos unlabeled for before and after and arranged in non-chronological order. Reviewers were asked to determine before and after photos and the degree of improvement in scarring, textural change, and post-inflammatory hyper-pigmentation (PIH) secondary to the acne or scarring condition. Degree of improvement was graded using a four-point scale: $0 = <25\%$, $1 = 25–50\%$, $2 = 51–75\%$, $3 = 76–100\%$.

Results: Based on blinded photo assessments by three independent reviewers, clinically and statistically significant median improvement of 2 in scarring, 2.3 in texture, and 2 in pigment were observed (one-sample Wilcoxon signed rank test, $P < 0.001$). Reviewers were highly consistent (inter-reviewer reliability) in identification of before and after photos (kappa of 0.88).

Conclusions: Preliminary data collected in this retrospective study suggest that sub-millisecond 1,064 nm Nd:YAG laser treatment is a safe and effective treatment for atrophic scarring in patients with darker skin types, delivering clinically and statistically significant results with reduced risk of pigment complications and patient discomfort. Lasers Surg. Med. 43:130–136, 2011.
© 2011 Wiley-Liss, Inc.

Key words: non-ablative; Nd:YAG; darker skin types; atrophic scar; post-inflammatory hyper-pigmentation (PIH); laser

BACKGROUND

Darker skin presents a significant challenge to laser practitioners. Treatment options are limited due to increased risks of pigmentary complications including hypo- and hyper-pigmentation. This is especially true when attempting to treat large areas with atrophic scarring.

Current methods of treating scarring include traditional fully ablative erbium and carbon dioxide (CO_2) treatments as well as non-ablative and ablative fractional resurfacing with CO_2, erbium:yttrium-aluminum-garnet (Er:YAG), and erbium:yttrium-scandium-galium-garnet (Er:YSGG) lasers [1–8]. These options can be challenging for skin type IV patients and not feasible for patients with skin types V–VI without significant pre- and post-treatment skin conditioning and a hyper-pigmentation risk. With traditional fully ablative CO_2 resurfacing, studies showed hyper-pigmentation rates of 20–30% in Fitzpatrick skin type III and nearly 100% in skin type IV if treatment is performed

without pre-treatment prophylaxis [9–11]. Further, 19% of traditional resurfacing patients experience some form of hypo-pigmentation. A recent study on the treatment of acne scarring with fractionated Erbium-doped YAG laser reported a post-inflammatory hyper-pigmentation (PIH) incidence of 50% in 15 subjects with skin types IV–VI [12].

When the 1,064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser with the option of sub-millisecond pulse width is used with 300–500 microsecond pulse durations, a 5 mm spot size and repetition rates of 5–10 Hz, it offers the ability to focus heat in the papillary and upper reticular dermis. The sub-millisecond 1,064 nm Nd:YAG laser has been proven to stimulate new collagen synthesis [13]. It is therefore feasible that deliberate sub-millisecond 1,064 nm Nd:YAG laser treatments could result in substantial reduction in scarring by stimulating collagen formation resulting in smoothing of the skin.

OBJECTIVES

The primary objective of this retrospective study is to determine the safety and efficacy of this unique pulse modality to reduce the signs of atrophic scarring, texture, and PIH secondary to the acne condition in darker skin types. The secondary objective is to assess the incidence of PIH resulting from the laser treatments.

STUDY DESIGN AND METHODS

This is a retrospective study evaluating the safety and efficacy of a sub-millisecond 1,064 nm Nd:YAG laser. Treatments were conducted at the National Institute of Laser Enhanced Sciences, Dermatology Unit, at Cairo University, Egypt and at Saheroun Hospital, Khartoum, Sudan on 22 patients with Fitzpatrick skin types III ($n = 2$), IV ($n = 4$), V ($n = 14$), VI ($n = 2$) who had atrophic scarring such as acne scarring. All patients who were treated over a 6-month period between February and July of 2008 were included in the study.

Treatments were performed using 300–500 microseconds pulse duration, 14–16 J/cm^2 and 5–7 Hz repetition rate. The hand piece was held 1–2 cm off the surface of the skin (about the width of an index finger) during delivery. Treatments were performed without topical anesthesia. No prophylactic therapy was used before or after treatment to control PIH resulting from laser treatments. On average, each patient received six treatments (minimum 5, maximum 7). The average interval between treatments was 24.5 days with a range from 18.7 to 33.0 days. Follow-up photographs were taken, on average, 9 months (range of 3–10 months) after the final treatment. Patient ages ranged from 18 to 47 years with a mean of 28.6 years. The average number of pulses per procedure was 11,700 pulses ranging from 8,000 to 13,900 pulses. The patient-to-patient variation in the number of pulses was associated with the size of the surface area treated, not with the treatment indication. Treatment parameters used on each patient are listed in Table 1.

To optimize laser results, the skin was treated with micro-dermabrasion (MDA) throughout the sub-millisecond 1,064 nm Nd:YAG laser treatment series. Ten sessions of MDA were administered with an interval of 7–10 days between each session. A minimum of 3 days was allowed between MDA and laser treatments.

TABLE 1. Treatment Parameters and Follow-Up Times

Patient	Age	No. of pulses per treatment	No. of treatments	No. of days between treatments	Follow-up post-final treatment (months)
1	25	10,000	6	20.2	9
2	22	11,500	5	21	3
3	36	12,400	7	22.5	9
4	26	11,800	7	31	9
5	29	13,400	7	23	8
6	42	10,000	5	24.2	9
7	24	10,400	7	23.2	8
8	27	12,000	7	26.8	9
9	22	13,700	6	18.7	10
10	29	11,800	6	22	10
11	23	12,000	6	23.1	9
12	40	10,200	5	29	10
13	28	15,000	6	22.6	9
14	18	12,500	6	20.6	9
15	21	12,000	6	22.2	10
16	25	13,800	7	27.3	9
17	30	13,900	5	21.7	9
18	26	8,600	6	28.6	9
19	31	9,700	5	21	10
20	27	12,400	5	26.7	10
21	32	12,300	6	30.7	9
22	47	8,000	6	33	9
Average	28.64	11,700	6	24.5	9

Following the MDA treatment, the whole face was treated with the sub-millisecond 1,064 nm Nd:YAG laser. No additional passes were applied on the areas of atrophic scarring. The hand piece was held 1–2 cm off the face with continuous motion to build heat and erythema in the treatment area prior to moving to an adjacent part of the face. The surface area for each treatment region was approximately 5 cm × 5 cm square. The total and average number of pulses per treatment, and the total number of treatments per patient are also shown in Table 1.

Three independent physician reviewers (two dermatologists and one plastic surgeon) were asked to identify the before and after treatment photos which were presented to the physicians for assessment in random order. After selecting the before and after image, reviewers were asked to rank the degree of improvement in scarring, texture, and PIH using a four-point scale (0 = <25%, 1 = 25–50%, 2 = 51–75%, 3 = 76–100%). Any indication which did not apply to a patient was marked as N/A. The median improvement score was calculated based on scores from all three reviewers. When the before photo was incorrectly selected as the after photo (one case only), the negative value of the improvement score was used in calculating the median score taking into account the magnitude of deterioration as assessed by the reviewer. This was done instead of excluding this case to avoid any bias in the data analysis.

Patients were evaluated for erythema, edema, purpura, blistering, crusting, hypo- and hyper-pigmentation, and scarring. Patients were also asked if they observed any adverse reaction of the above or any other skin reaction they consider adverse between visits.

Statistical Analysis

Statistical analysis was performed using Minitab statistical package, version 15.1.20.0 (Minitab, Inc., State College, PA). For statistical testing, two-sided one-sample Wilcoxon signed rank test was used, and P values <0.05 were considered statistically significant. Additionally, the medians and spread of the data were displayed in box plot graph. Kappa agreement analysis [14,15] was performed to measure the inter-reviewer reliability of before and after photos assessments and the kappa coefficient was reported.

RESULTS

Blinded Photo Assessments

Two reviewers correctly identified all photos (22/22). The third reviewer incorrectly labeled one pair of before and after images and was not able to identify another pair of photos due to insufficient image quality (20/22). The reviewers were highly consistent (inter-reviewer reliability, kappa of 0.88) in identification of before and after photos (kappa coefficient: poor <0.20, fair 0.21–0.40, moderate 0.41–0.60, good 0.61–0.80, and very good 0.81–1.00).

Of the 66 possible image reviews for each category (22 images each reviewed by three physicians), one was determined by one reviewer as insufficient quality to grade before and after. Additionally, four images were excluded from scarring analysis, four were excluded from texture analysis,

and five were excluded from pigment analysis. Images were excluded due to insufficient focus, color balance, and/or lighting.

The results of the blinded photo assessments indicated clinically and statistically median improvement of 2 in scarring, 2.3 in texture, and 2 in PIH ($P < 0.001$). Figure 1 displays the median improvement scores and the variability of data for all three conditions (scale of 0–3).

Figure 2 displays photos from seven different patients with follow-up times. Subject characteristics and treatment parameters used on a particular patient can be found in Table 1.

Transient mild edema and erythema were observed in all patients and resolved within 2 hours after treatment.

No transient or permanent complications such as blistering, crusting, purpura, scarring, transient or permanent hyper- or hypo-pigmentation were noted.

There was no single patient who reported any adverse effects during or after the treatment sessions till the end of the follow-up period in this study.

DISCUSSION

Retrospective photographic analysis of 22 cases in this study indeed shows that sub-millisecond 1,064 nm Nd:YAG laser may be a viable treatment modality capable of generating improvement in texture, scarring, and PIH secondary to the acne condition in darker skin types. Blinded photo assessments by three independent physicians indicated that six treatments performed, on average, 24.5 days apart resulted in clinically and statistically significant improvement in atrophic scarring, texture, and PIH in patients with skin types III–VI. High consistency between reviewers was observed in identifying before and after photos.

It is noteworthy to state that (1) the non-invasive treatments with the sub-millisecond 1,064 nm Nd:YAG laser improved the existing PIH from acne scarring; (2) did not induce additional PIH; (3) did not require pre- and post-treatment agents to control PIH in dark skin patients; (4) did not require anesthetic.

The percentage of subjects with skin types IV and V included in studies for the treatment of atrophic scarring are very limited compared to lighter skin types due to pigmentation concerns [1–3]. Even with the use of hydroquinone pre- and post-treatment, a recently published prospective study of 15 subjects with skin types IV–VI and acne scarring using Erbium-doped YAG laser showed a 50% rate of the PIH [12]. In the same study, the pain levels were reported to increase as the skin type went from IV to VI and as the number of passes went from 1 to 8.

One challenge faced in this retrospective study was not all patient photos had sufficient image quality. As a result, a couple of photos were excluded from the data analysis. The second challenge was the data only captured an overall percentage improvement without assessments of severity and types of scars at baseline and follow-up. This was due to the lack of high-resolution standardized photos. In future studies, high-resolution photos of scarring (using macro lens settings without flash [7] or a three-dimensional optical

Fig. 1. Median improvement of 2 in scarring, 2.3 in texture, and 2 in pigment based on blinded photo assessments by three reviewers. The box illustrates the 25th percentile to the 75th percentile with a line placed at the median (50% percentile). The bottom and top ends of whiskers show the minimum and maximum, respectively.

profiling system) should be used for objective assessment of scar severity and type [6,8]. Lastly, it would be beneficial to collect data on patient satisfaction in addition to physician assessments.

The theory behind combining MDA treatments with laser treatments was to reduce the thickness of the stratum corneum thereby allowing greater light penetration to the papillary dermis. Thus, MDA treatments performed before the laser treatments were mild in intensity to prevent discomfort or complications from deep dermal abrasions [16]. The conservative MDA settings used in this study were not considered effective to treat acne scarring and PIH and were unlikely to have had an effect on the observed improvement [17–19]. Nonetheless, randomized split face studies would be required to definitely determine whether MDA is necessary or has an additional benefit when used in combination with laser treatments.

In previous studies, the sub-millisecond 1,064 nm Nd:YAG laser therapy has been shown to stimulate collagen [13] and to improve scar severity [20]. However, no assessment has been performed on secondary improvement to texture and pigment. We hypothesize that the sub-millisecond Nd:YAG laser works through two parallel actions to safely stimulate collagen and improve discoloration. The first mechanism involves discrete cellular damage caused by direct absorption in hemoglobin, melanin, and water during each pulse and bulk heating from cumulative pulsing in a region. As a result, damage created through direct absorption and through sustained time at elevated temperature initiates a healing response, prompting collagen stimulation [21,22].

Nd:YAG is absorbed by melanin and hemoglobin and is subsequently used for vascular and hair reduction treatments. Pulse durations in these treatments are in the 10–100 milliseconds range, roughly 30–300 times longer than the pulse durations used in this study. The short pulse durations used in sub-millisecond treatment does not change the characteristics of chromophore absorption. At these short pulse durations, the laser energy is heating fine structures during each pulse, thus more selectively targeting the microvasculature in the papillary dermis and melanocytes within the epidermis without actually damaging the epidermis or larger vessels in the dermis.

The second mechanism of action occurs through bulk heating. The laser uses a 5 mm spot pulsing at 5–10 Hz to deliver large amounts of energy in relatively short bursts to a finite area of tissue. Heat conducts to surrounding tissue over time to create bulk heating in each treatment. The degree of bulk heating is a function of total energy delivered per unit area per unit time. The goal during treatment is to deliver energy to an area of tissue faster than the body can extract the heat. For this reason, skin cooling is not desired during treatment. This bulk heating occurs gradually and non-selectively through heat conduction, so no structures are specifically targeted. This allows for safe treatment, even on type VI skin.

CONCLUSIONS

Preliminary data collected in this retrospective study suggest that sub-millisecond 1,064 nm Nd:YAG laser treatments are safe and effective for treating atrophic scarring in

Patient 1: (1a) Baseline, (1b) 9 months post-final treatment (6 sessions)

Patient 3: (3a) Baseline, (3b) 9 months post-final treatment (7 sessions)

Patient 4: (4a) Baseline, (4b) 9 months post-final treatment (7 sessions)

Patient 13: (13a) Baseline, (13b) 9 months post-final treatment (6 sessions)

Patient 14: (14a) Baseline, (14b) 9 months post-final treatment (6 sessions)

Fig. 2. Patient photos (1, 3, 4, 13, 14, 15, 20) at baseline and at follow-up visit after final treatment. Patient 1: (**a**) Baseline, (**b**) 9 months post-final treatment (six sessions). Patient 3: (**a**) Baseline, (**b**) 9 months post-final treatment (seven sessions). Patient 4: (**a**) Baseline, (**b**) 9 months post-final treatment (seven sessions). Patient 13: (**a**) Baseline, (**b**) 9 months post-final treatment (six sessions). Patient 14: (**a**) Baseline, (**b**) 9 months post-final treatment (six sessions). Patient 15: (**a**) Baseline, (**b**) 10 months post-final treatment (six sessions) Patient 20: (**a**) Baseline, (**b**) 10 months post-final treatment (five sessions).

Fig. 2. (*Continued*)

patients with darker skin types, delivering clinically and statistically significant results with reduced risk of pigment complications. This offers a new standard of care or first treatment option for patients with a high risk of pigmentary complications. Prospective studies with the sub-millisecond Nd:YAG laser alone are required to further assess treatment outcomes considering the effect of number treatments as well as to determine targeted treatment parameters for improved effects on scars of various severity and type. Further, randomized split face studies are needed to show the treatment effect and the incidence of PIH compared to non-treated and treated controls with alternative treatments.

ACKNOWLEDGMENTS

REFERENCES

1. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. Dermatol Surg 2007;33(3): 295–299.
2. Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. Dermatol Surg 2008;34(10): 1327–1332.
3. Kim S, Cho KH. Clinical trial of dual treatment with an ablative fractional laser and a non-ablative laser for the treatment of acne scars in Asian patients. Dermatol Surg 2009;35(7): 1089–1098.
4. Cho SB, Lee SJ, Kang JM, Kim YK, Chung WS, Oh SH. The efficacy and safety of 10,600-nm carbon dioxide fractional laser for acne scars in Asian patients. Dermatol Surg 2009;35(12): 1955–1961.
5. Cho SB, Lee SJ, Cho S, Oh SH, Chung WS, Kang JM, Kim YK, Kim DH. Non-ablative 1550-nm erbium-glass and ablative 10,600-nm carbon dioxide fractional lasers for acne scars: A randomized split-face study with blinded response evaluation. J Eur Acad Dermatol Venereol 2009;17:1–5.
6. Chapas AM, Brightman L, Sukal S, Hale E, Daniel D, Bernstein LJ, Geronemus RG. Successful treatment of acneiform scarring with CO_2 ablative fractional resurfacing. Lasers Surg Med 2008;40(6): 381–386.
7. Deng H, Yuan D, Yan C, Lin X, Ding X. A 2940 nm fractional photothermolysis laser in the treatment of acne scarring: A pilot study in China. J Drugs Dermatol 2009;8(11): 978–980.
8. Walgrave SE, Ortiz AE, MacFalls HT, Elkeeb L, Truitt AK, Tournas JA, Zelickson BD, Zachary CB. Evaluation of a novel fractional resurfacing device for treatment of acne scarring. Lasers Surg Med 2009;41(2): 122–127.
9. Dover J, Arndt K, Geronemus RG, Alora MB. Laser resurfacing. In: Dover Jeffrey S., Arndt Kenneth A. editors. Illustrated cutaneous & aesthetic laser surgery. Stanford: Appleton & Lange 2000: 81–112.
10. Goldman MP, Weiss RA. Laser resurfacing with the UPCO2+Er:YAG lasers. In: Goldman Mitchel P., Weiss Robert editors. Advanced techniques in dermatologic surgery. New York: Taylor & Francis 2006: 219–239.
11. Fitzpatrick RE. Skin resurfacing with carbon dioxide and erbium lasers. In: Goldman MP, Fitzpatrick RE editors. Cutaneous laser surgery. St. Louis: Mosby 1999: 339–436.
12. Mahmoud BH, Srivastava D, Janiga JJ, Yang JJ, Lim HW, Ozog DM. Safety and efficacy of erbium-doped yttrium aluminum garnet fractionated laser for treatment of acne scars in type IV to VI skin. Dermatol Surg 2010;36(5): 602–609.
13. Schmults CD, Phelps R, Goldberg DJ. Non-ablative facial remodeling erythema reduction and histologic evidence of new collagen formation using a 300-microsecond 1064-nm Nd:YAG laser. Arch Dermatol 2004;140:1373–1376.
14. Altman DG. Practical Statistics for Medical Research. In: Freedman D., Pisani R., Purves R., Statistics. London: Chapman and Hall 1991.
15. Viera AJ, Garrett JM. Understanding interobserver agreement: The kappa statistic. Fam Med 2005;37(5): 360–363.
16. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: An evidence-based review. Plast Reconstr Surg 2010; 125(1): 372–377. Review.
17. Tsai RY, Wang CN, Chan HL. Aluminum oxide crystal microdermabrasion: A new technique for treating facial scarring. Dermatol Surg 1995;21(6): 539–542.
18. Shim EK, Barnette D, Hughes K, Greenway HT. Microdermabrasion: A clinical and histopathologic study. Dermatol Surg 2001;27(6): 524–530.
19. Wang SQ, Counters JT, Flor ME, Zelickson BD. Treatment of inflammatory facial acne with the 1,450 nm diode laser alone versus microdermabrasion plus the 1,450 nm laser: A randomized, split-face trial. Dermatol Surg 2006;32(2): 249–255; discussion 255.

20. Lipper G, Perez M. Non-ablative acne scar reduction after a series of treatments with a short-pulsed 11,064-nm Neodymium:YAG laser. Dermatol Surg 2006;32:998–1006.

21. Trelles MA, Alvarez X, Martín-Vázquez MJ, Trelles O, Velez M, Levy JL, Allones I. Assessment of the efficacy of non-ablative long-pulsed 1064-nm Nd:YAG laser treatment of wrinkles compared at 2, 4, and 6 months. Facial Plast Surg 2005; 21(2): 145–153.

22. Yeh AT, Kao B, Jung WG, Chen Z, Nelson JS, Tromberg BJ. Imaging wound healing using optical coherence tomography and multiphoton microscopy in an in vitro skin-equivalent tissue model. J Biomed Opt 2004;9(2): 248–253.

Taylor & Francis
Taylor & Francis Group

ORIGINAL ARTICLE

Treatment of genital warts in males by pulsed dye laser

ASHRAF BADAWI[1,2], HISHAM A. SHOKEIR[1], AHMED M. SALEM[3], MONA SOLIMAN[1], SAHAR FAWZY[4], NEVINE SAMY[1] & MANAL SALAH[1]

[1]*National Institute of Laser Enhanced Sciences (NILES), University of Cairo, El-Giza, Egypt,* [2]*Szeged University, Hungary,* [3]*Department of Andrology and Sexually Transmitted Diseases, Cairo University Hospital, Cairo, Egypt, and* [4]*Department of Dermatology and Venereology, Azhar University, Cairo, Egypt*

Abstract

Objective: To determine the safety and efficacy of the flashlamp-pumped pulsed dye laser for the treatment of uncomplicated genital warts in adult males.

Methods: This was a prospective observational study set in the outpatient clinics of the Department of Andrology and Sexually Transmitted Diseases, National Institute of Laser Enhanced Sciences, the Dermatology Clinic, Cairo University, and the Department of Dermatology and Venereology, Suez Canal University. A total of 174 adult male patients with 550 uncomplicated anogenital warts were included. Selective photothermolysis and photocoagulation of the lesions with the flashlamp-pumped pulsed dye laser was carried out. A pulsed dye laser (wavelength 585 nm, 450 s pulse duration; Cynosure, USA) was used with the following settings: spot size 5–7 mm; fluence 9–10 J/cm^2.

Results: Complete resolution of treated warts was achieved in 96% of lesions. Side effects were limited, transient and infrequent. Lesion recurrence rate was 5%.

Conclusion: The pulsed dye laser has been found to be safe, effective and satisfactory for the treatment of anogenital warts in males. It could be used to selectively destroy warts without damaging the surrounding skin.

Key words: *Genital warts, pulsed dye laser*

Introduction

A written description of condylomatous warts of the genital tract and anus dates as far back as the first century AD (1,2). Within the first decade of the last century, the viral etiology of genital warts was demonstrated (3). At least 35 of over 100 different human papillomavirus (HPV) types primarily infect genital epithelium (4,5). Although most external genital warts are positive for HPV 6 or 11 DNA, and most invasive squamous cell cancers of the genital tract and anus are positive for HPV 16, 18, 31, 33, or 45 DNA, squamous intraepithelial lesions (SILs) of the cervix, vagina, vulva, penis and anus are associated with many different HPV types (6).

Genital HPV infections are transmitted primarily through sexual contact, with an average incubation period of 2 months. The majority of newly acquired genital HPV infections appear to be subclinical and asymptomatic. Clinically visible manifestations of HPV include warts that may be condylomatous, papular, flat, or keratotic in appearance. Subclinical infections may appear as flat 'aceto-white' lesions

that are visible with colposcopic magnification of epithelium that has been treated with a mild acetic acid (vinegar) solution, or as SILs that are diagnosed microscopically on the basis of characteristic cytologic and histologic features (7).

A number of years after initial infection, some individuals with HPV are at risk of developing squamous cell carcinoma (8). Individuals presenting with genital warts rarely report symptoms other than the appearance of new bumps or growths on their genitalia. Occasionally, patients will report itching, burning, pain, or bleeding. Some, perhaps most, individuals with genital warts never become aware of their presence (9).

In males, most genital warts occur on the penis, scrotum, urethral meatus and perianal area (10). Because genital warts frequently occur with more than one lesion on the genital site and with lesions on different genital sites, it is important to examine the entire genitalia. Use of (3–5%) acetic acid solution to detect 'subclinical' HPV infections of the external genitalia is not recommended because

the predictive value and therapeutic benefit of this procedure has not been established (11).

The four morphologic types of genital warts are condylomata acuminata, which have a cauliflower-like appearance; papular warts, which are flesh-colored, dome-shaped papules, usually 1–4 mm in diameter; keratotic warts, which have a thick, crust-like layer and may resemble common skin warts or seborrheic keratosis; and flat-topped papules, which appear macular to slightly raised. In general, condylomata are most frequently detected on moist, partially keratinized epithelium, papular and keratotic warts on fully keratinized epithelium, and flat papular warts on either partially or fully keratinized epithelium (10,12,13). Genital wart therapies are classified as patient-applied or provider-administered.

Patient-applied treatments include podofilox solution and gel, and imiquimod cream (14,15). To self-treat, patients must be able to identify and reach the warts and to follow the treatment application instructions. The provider-administered treatments include topical treatments (cryotherapy, podophyllin resin, trichloroacetic acid, bichloroacetic acid, and external application and intraurethral instillation of bacillus Calmette–Guerin); excisional treatments (curettage, electrosurgery, scissors excision, or laser vaporization); or injectable treatments (interferon or 5-fluorouracil/epinephrine gel implant) (15–24).

Tuncel et al. (24) used the pulsed dye laser for treatment of perianal warts in children. They found the pulsed dye laser to be effective and less traumatic compared with other treatment options. To the best of our knowledge, there are no previous studies evaluating the role of the pulsed dye laser in the treatment of genital warts in adult males.

Based on these data, the aim of this study was to determine the safety and efficacy of the flashlamp-pumped pulsed dye laser for the treatment of uncomplicated genital warts in adult males.

Patients and methods

The present study was carried out on adult males with anogenital warts. They were recruited from patients attending the outpatient clinics of the Department of Andrology and Sexually Transmitted Diseases, National Institute of Laser Enhanced Sciences, the Dermatology Clinic, Cairo University, and the Department of Dermatology and Venereology, Azhar University. History taking was done with special emphasis on age, marital status and extramarital relations, including homosexual practice, duration and course of lesions, associated urethral discharge, genital ulceration, skin rash, previous treatments, and any similar condition in the patient's wife or sexual partner(s).

General examination for the whole body, including the oral mucosa, was done for signs of sexually transmitted diseases (STDs) (for example, vesicles, ulcers, warts, mucous patches, lymph node enlargement).

Local genital examination was done while the patients were completely uncovered from the umbilicus down to the knee. The skin of the lower abdomen, penis, scrotum, perineum, perianal area, upper thighs, and the urethral meatus were inspected under good illumination for the presence of warts and other STDs. In all settings, patients with genital warts were examined and treated for other STDs. Whenever possible, their wives or current sexual partners were also offered examinations and treatments for macroscopically visible warts and other STDs. Examination of the anogenital warts was done and the following data were recorded: site, number, type, area, presence of complications such as ulcerations or bleeding. The wart area was estimated as follows: the two largest perpendicular diameters were measured, and the wart area was defined as the product of the two measurements.

Finally, a total of 174 adult males with 550 uncomplicated anogenital warts and with no history of topical or systemic therapy for warts during the last 2 months were included and treated by pulsed dye laser. A pulsed dye laser (585 nm, 450 s pulse duration; Cynosure, USA) was used with the following parameters: spot size 5–7 mm according to the size of the lesions, and fluence 9–10 J/cm^2. Overlapping pulses were done, up to three to four pulses, until the appearance of grayish discoloration of the lesions which was an end point for lesion coagulation.

Treatments were repeated every 2 weeks with a maximum of three sessions. Topical antibiotic ointments were prescribed between the sessions to be used for a period of 7–10 days following every session. The number of warts, and the area of warts at presentation and at the end of treatment was recorded. Any adverse reactions were also recorded. Patients were followed-up for at least 4 months after the warts had cleared.

Results

The mean age of patients included was 31.33 ± 4.7 years (range from 22 to 49). The mean duration of lesions was 4.29 ± 3.15 months (range from 1 to 48). The number of warts ranged from one to 14 per patient (average 3.82 ± 4.33). Warts were frequently present with more than one lesion on one anatomical site. Warts were also present more frequently on different genital sites (104 patients, 59.78%) and on one genital site in 70 patients (40.22%). Among those latter patients, lesions were present on the penis in 39 (22.41%), on the scrotum in 11 (6.32%),

on the urethral meatus in four (2.29%), and on the perianal area in 16 (9.2%). The mean area of lesions was 26.9 mm^2 and the area varied from 6 mm^2 to 64 mm^2. With regard to the morphological type of warts detected, it was predominantly condylomatous in 129 patients, papular in 31, keratotic in nine, and flat-topped papules in five patients.

Complete clearance of 528 anogenital warts (96%) treated by pulsed dye laser occurred after one to three sessions. A few small warts of short duration occurring on one anatomical site cleared significantly after fewer sessions and resulted in earlier clearance. Patients with fewer than three and with an area less than 20 mm^2 cleared most frequently after one session. Other factors such as a patient's age and the morphological type did not affect the treatment results. Overlapping pulses (three to four) revealed better clearance of warts than single and even double pulsing. Side effects were infrequent and transient, mostly in the form of mild pain at treatment and transient hypopigmentation after treatment. Patients were followed-up for at least 4 months (up to 9 months in some cases). Complete resolution and healing of skin without scaring or texture changes were found in the

(A)

(B)

Figure 1. A penile condylomata acuminate: (A) before treatment; (B) after treatment (three sessions).

majority of cases (Figure 1). Lesion recurrence rate was 5%. Recurrence was defined as a new wart at the same site detected within the 4-month follow-up period after clearance of lesions.

Discussion

Management of genital warts presents a problem of increasing magnitude to genitourinary medicine. Choice of treatment is guided by patient preference, with consideration given to the patient's age and ability to comply with moderately complicated directions, to the location and number of warts, and to the clinician's training. Many conventional lines of therapy are used, the aim of which is to destroy the infected tissue; however, none are consistently effective, making genital warts a therapeutic challenge. Laser therapy had been used for the treatment of genital warts since the 1970s (25). CO_2, argon, Nd:YAG and Er:YAG lasers have been used, especially for refractory genital warts, giant condyloma acuminatum or Buschke–Lowenstein tumor, with variable degrees of safety and efficacy (26–30).

The pulsed dye laser was used initially for selective photothermolysis of vascular lesions, whereby the wavelength is selectively absorbed by the oxyhemoglobin, leading to destruction of the vascular component of the tissue. It was also used in the management of other non-vascular lesions, depending on the photothermal effect of laser on the cutaneous tissue $\pm$ its selective photothermolysis effect. The pulsed dye laser was used for the management of simple and recalcitrant verrucae vulgaris on different sites of the body using fluencies ranging from 6 to 9 J/cm^2 (31). Other studies reported higher fluencies of 9.4 J/cm^2 giving variable clearance rates (32).

Tuncel et al. (24) used the pulsed dye laser for the management of perianal warts in children with a fluence of 7.5 J/cm^2. In our study, we used higher fluencies of 9–10 J/cm^2, which ensured greater destruction of the vascular component of the lesions. The overlapping pulses increased the photothermal effect of the laser radiation leading to coagulation of the lesions and immediate graying of the warty tissue. The technique was done as an outpatient procedure and did not require any infiltration anesthesia as in electrocautery or surgery, which is another advantage of the pulsed dye laser in the treatment of genital warts. It is safe in comparison to the toxicity of podophyllotoxins, which are continuously investigated in an attempt to increase efficacy and decrease toxicity (18). In the light of results from our study, in which there was a significant number of patients presenting with multiple and/or large size 5 lesions, complete resolution and healing of skin without scaring or texture changes were found in the majority of cases. This is in contrast

with what is usually found with other traditional treatments such as electrocautery, surgical excision, cryotherapy or CO_2 laser.

Lesion clearance rate in our study was 96%, which is superior to that achieved by the more widely used treatment modalities (32–88%) (11,15). Better results (smaller number of sessions and earlier clearance) were observed with lesions of short duration and in cases with a small number of warts occurring on one anatomical site. On the other hand, failure of treatment that occurred only in 4% of cases was observed in highly recalcitrant lesions with a large number of warts, which might be attributed to increased fibrosis and hyperkeratosis due to previous attempts of treatment. Lesion recurrence rate (5%) was also less than reported with other treatment modalities (8–22%) (16). Post-treatment recurrence rates are not well defined in most studies because in most cases either too few subjects have been studied or follow-up protocols had not been standardized (11).

In conclusion, the pulsed dye laser has been found to be a safe, effective, and satisfactory treatment for genital warts. It is capable of selectively destroying warts without damaging the surrounding skin.

References

1. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971;47:1.
2. Rosenbaum J. The plague of lust. Being a history of venereal disease in classical antiquity, and including detailed investigations into the cult of Venus and phallic worship, brothels, etc. Paris: C. Carrington; 1901. (Cited by Koutsky and Kiviat, 1999. Ref. No. 11.)
3. Cobb MW. Human papillomavirus infection. J Am Acad Dermatol. 1990;22:547–66.
4. Zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol. 1996; 122:3.
5. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 1994;54:4610.
6. Bouscarat F, Mahe E, Descamps V. External anogenital condylomas. Ann Dermatol Venereol. 2002;129:1013.
7. Wright TC. Precancerous lesions of the cervix. In: Kurman R, editor. Blausteins pathology of the female genital tract. 4th ed. New York: Sringer-Verlag; 1994. p. 229–77.
8. IARC Working Group. Studies of cancer in humans. In: IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Lyon, 1995. p. 187–231.
9. Kinghorn GR. Genital warts: incidence of associated genital infections. Br J Dermatol. 1978;99:405.
10. Wikstrom A. Clinical and serological manifestations of genital human papillomavirus infection. Acta Derm Venereol Suppl (Stockh). 1995;193:10.
11. Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, et al., editors. Sexually transmitted diseases. 3rd ed. Vol. 1. New York, St Louis, San Francisco, London, Paris, Tokyo, Toronto: McGraw-Hill Health Profession Division; 1999. p. 347–59.
12. Rowson KEK, Mahy BWJ. Human papova (wart) virus. Bacteriol Rev. 1967;31:110.
13. Meisels A, Fotin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol. 1976;20:505.
14. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% 6 podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminate in males and females. Int J STD AIDS. 1993;4:194.
15. Beutner KR, Ferenczy A. Therapeutic approaches to genital warts. Am J Med. 1997;102:28.
16. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11:598.
17. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens LL, et al. Imiquimod, a patient-applied immunoresponse modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42: 789–94.
18. Bohle A, Doehn C, Kausch I, Jocham D. Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-Guerin. J Urol. 1998;160:394.
19. Metawea BA, Elnashar AM, Ismail IK, Kasem W. Application of viable bacillus Calmette-Guerin topically as a primary treatment in condylomata acuminata. MSc Thesis. Cairo: Cairo University Press; 2002.
20. Gay C, Terzibachian JJ, Gabelle C, Reviron S, Ramanah R, Mougin C. Carbon dioxide laser vaporization of genital condyloma in pregnancy. Gynecol Obstet Fertil. 2003; 31:214.
21. Mahmoud KZ, Mo'men MN, Mostafa T, Roaia MMF, Anis TH, Salem AM. Evaluation of the role of interferon alpha 2B in the treatment of condylomata acuminata. Egypt J Androl Reprod. 1993;7:81.
22. Condylomata International Collaborative Study Group. Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon α-2a in the treatment of anogenital condylomata acuminata. J Infect Dis. 1993;167:82.
23. Swinehart JM, Sperling M, Phillips S, Kraus S, Gordon S, McCarty JM, et al. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata: a phase III clinical study. Arch Dermatol. 1997;133:67.
24. Tuncel A, Gorgu M, Ayhan M, Deren O, Erdogan B. Treatment of anogenital warts by pulsed dye laser. Dermatol Surg. 2002;28:350.
25. Vainberg ZS, Vishnevskii AA, Likhter MS. Use of lasers for surgical treatment of urethral polyps and condylomata acuminata of the penis. Urol Nefrol. 1977;2:44.
26. Fuselier HA Jr, McBurney EI, Brannan W, Randrup ER. Treatment of condylomata acuminata with carbon dioxide laser. Urology. 1980;153:265.
27. Patrice T, Dreno B, Jutel P, Cloarec D, Barriere H, Le Bodic L. The role of the argon laser in the treatment of condylomata acuminata of the anal margin and canal. Ann Gastroenterol Hepatol. 1985;5:283.
28. De la Campa MMA, Moreno RJA, Ochoa PJ. Treatment of giant vulvar condylomata acuminata combining CO_2 laser and electrosurgery. Gynecol Obstet. 2003;68:27.
29. Zaak D, Hofstetter A, Frimberger D, Schneede P. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology. 2003;5:1011.
30. Wollina U. Er:YAG laser followed by topical podophyllotoxin for hard to treat genital warts. J Cosmet Laser Ther. 2003;1:35.
31. Kenton-Smith J, Tan ST. Pulsed dye laser therapy for viral warts. Br J Plast Surg. 1999;52:554.
32. Ross BS, Levine VJ, Nehal K, Tes Y, Ashinoff R. Pulsed dye laser treatment of warts: an update. Dermatol Surg. 1999;25:377.

Flache Warzen können erfolgreich mit einem langgepulsten Nd-YAG Laser behandelt werden

Plane warts can be managed successfully using long pulsed Nd-YAG laser

Nevien Samy[1], Manal Salah[2], Mona Soliman[3], Ashraf Badawi[4]

Schlüsselwörter
Nd-YAG laser, flache Warzen

Zusammenfassung

Hintergrund: Die am häufigsten vorkommenden Warzen sind flache Warzen. Bis heute gibt es keine Behandlungsmethode die 100prozentig sicher und effektiv ist in der Entfernung von Warzen. Herkömmliche Behandlungsmethoden fokussieren auf die Zerstörung infizierten Gewebes mittels vielfältiger Techniken. Ziel: Evaluierung des langgepulsten Nd-YAG Lasers in der Behandlung flacher Warzen. Selektion der wirksamsten Laserparameter für die Destruktion, ohne Nebenwirkungen.

Patienten und Methodik: 42 Patienten nahmen an der Studie teil. Die Patienten klagten über persistierende Warzen auf Stirn, Wangen, Kinn, Hals, Armen und Handrücken. Zur Behandlung wurde ein langgepulster Nd-YAG Laser (1064 nm) eingesetzt und doppelt oder dreifach überlappende Impulse angewandt. Unser Endpunkt war die leicht gräuliche Verfärbung der Läsion. Ergebnisse: Bei 35 Patienten wurde ohne Komplikationen eine vollständige Remission der Warzen erreicht, während bei 7 Patienten nur eine Teilremission erreicht wurde. 4 Patienten klagten über postinflammatorische Hypopigmentation, die aber nach 8 Wochen spontan verschwand. Bei einem Patienten kam es zu postinflamma-torischer Hyperpigmentation. Nur in zwei Fällen kam es zu rezidiven innerhalb von drei Monaten. Alle Fälle wurden mindestens sechs Monate nach der letzten Behandlung nachuntersucht. Fazit: Der langgepulste Nd-YAG Laser kann effektiv und sicher, ohne Komplikationen, in der Behandlung flacher Warzen eingesetzt werden.

Key Words
Nd-YAG laser, plane warts

Summary

Background: Most common warts are flat warts. To date, no treatment method has been totally safe and effective in clearing warts. Traditional treatment modalities have focused on the destruction of infected tissue through a variety of techniques. Objective: Evaluation of long pulsed Nd-YAG laser for the treatment of plane warts. Selecting the most effective laser parameters for destruction without any side effects.

Patients and Methods: Forty-two patients were enrolled in the study. Patients complained from recalcitrant plane warts on the forehead, cheeks, chin, neck, arms and dorsum of the hands. Treat-ment was carried using long pulsed Nd-YAG laser (1064 nm) apply-ing double or triple overlapping pulses. Our end point was light greyish discoloration of the lesion.

Results: Thirty-five cases experienced complete clearance of their warty lesions without any complications, while partial response was observed in 7 patients. Four cases complained about post inflammatory hypopigmentation which lasted for eight weeks with spontaneous resolution. One case experienced post inflammatory hyperpigmentation. Two cases had recurrence of their lesions after three months. All the cases were followed up for at least six months after the last treatment session.

Conclusion: Long pulsed Nd-YAG laser can be used for treatment of plane warts as an effective, safe method with minimal complica-tions.

Introduction

Warts are benign epithelial neoplasm of the skin and mucosa result-ing from human papilloma virus infection. They are a common der-matologic complaint, with an estimated incidence of 10% in children and young adults. Treatment of warts can be difficult, with most approaches relying on physical destruction of infected keratinocytes. Common therapeutic approaches include liquid nitrogen, cryother-apy, topically applied acids, electro surgery, cantharidin application, bleomycin injection [1-6]. There have been several retrospective reviews of the use of pulsed dye laser, CO2 laser, KTP laser and Er-YAG laser therapy for warts. Initial reports appeared promising with significant clearance rates [7-11]. However, more recent studies have suggested that success may be more modest [10-12]. To date, there have been no trial evaluating the efficacy of long pulsed

Nd-YAG laser in the treatment of common warts. Our goal was to deter-mine response rates in such a fashion.

Material and Methods

Fifty patients with a total of 326 verrucae were enrolled in the study over 8 months period. They were 23 males and 27 females, with a mean age of 26.5 (12-41) years old. All patients were complaining of flat warts mainly on the forehead, cheeks, chin, neck, arms and the dorsum of the hands. Inclusion criteria included no treatment of lesions within the past month, and no history of constitutional or iatrogenic immunosuppression. All patients gave informed consent. The study was completed by 42 patients, which completion defined as clearance of all visible warts or a maximum of 3 treatment ses-sions on the same lesion.

[1] Lecturer of Dermatology, Dermatology Unit, NILES, Cairo University, Cairo, Egypt.
[2] Assistant Professor of Dermatology, Dermatology Unit, NILES, Cairo University, Cairo, Egypt.
[3] Professor f Dermatology, Dermatology Unit, NILES, Cairo University, Cairo, Egypt.
[4] Lecturer of Dermatology, Dermatology Unit, NILES, Cairo University, Cairo, Egypt, Visiting Lecturer, Szeged University, Hungary.

Treatment sessions consisted of treatment with the long pulsed Nd-YAG laser (1064 nm, Coolglide, Cutera, RIT 220 Excl.) with 20-30 msec. pulse duration and fluence between 95-110 J/cm^2, with 5,7 mm spot size according to the size of the lesion, applying double or triple overlapping pulses. Our endpoint was light greyish discoloration of the lesion.

Following treatment, there was slight perilesional erythema. Very minimal heat sensation or sometimes slight burning pain was experienced especially in children. Topical anaesthetic cream of 5% lido-caine and 3.5% prilocaine was used only in cases of children or with patients of low pain threshold. Treatment sessions were carried every 2 weeks with a maximum of 3 sessions on the same lesion. All patients and health care providers wore protective eyewear and micropore laser masks. A smoke evacuator was used as a precaution against potential aerosolised viral particles. Photographs were obtained at the initial visit and at 3 months follow up after the last treatment session.

Results

Of the 50 patients initially enrolled, 42 patients with a total of 256 warts completed the study. The 8 patients who withdrew, were for reasons unrelated to treatment. In the evaluation of treatment response, complete response was defined as complete absence of clinically apparent warts without any textural changes such as fibro-sis or scar formation. Partial response was defined as greater than 50 % reduction in wart size or number.

Complete response was observed in 35 patients (83.3%) Fig. 1-3, while partial response was observed in 7 patients (16.7%). No case showed no response to the lesion treatment. The mean number of treatments to achieve complete response was 2.00, while the mean number of treatments to achieve partial response was 2.65. Postoperative complications such as transient post inflammatory hypopig-mentation was observed only in 4 cases and only 1 case experienced transient post inflammatory hyperpigmentation and was given hydroquinone 4% cream. The recurrence of warts during follow up period was reported only in 2 cases. As regards patient satisfaction, ninety two percent of all patients even those who experienced partial response were satisfied with the treatment they were given.

Discussion

Common warts are hyperkeratotic papulonodules most often seen on the hand, arms and legs, but can seen anywhere on the glabrous skin. Common verrucae represent the most frequent clinical lesions produced by human papillomavirus [13]. Verruca plana (flat warts) are less exophytic than common warts, frequently presenting as sev-eral or dozen of subtle papules 2-6 mm in diameter elevated above the surface less than a millimetre or so. These can be quite subtle, and may be missed by a casual observer. Pigmentary disturbances may be the most disturbing part of the flat wart infection to the patient. These lesions are frequently a problem on the face and the glabrous skin of non-immunocompromised individuals. At present, therapies aim to remove the lesion rather than specifically target human papillomavirus infection. Many different types of therapy have been used in treatment of verrucae. Commonly used methods of physical destruction include: electrodessication, cryosurgery and laser therapy. Chemical destruction is induced with salicylic acid, cantharidin, among others. Chemotherapeutic agents include podophillin resin and 5-fluorouracil. More recently immunomodulators such as interferon, systemic retinoids have been used [14-16].

Many types of lasers have been used for the management of warts. Carbon dioxyde laser vaporization for infected tissue was used [17]. Results were not superior than the ordinary electrocautery which remove blindly the infected tissue as well and may sometimes lead to textural changes. Several investigators have demonstrated the efficacy of 585 nm pulsed dye laser in treating warts [7-12]. The mechanism of action may be a result of intense heating of dermal vessels with collateral damage of virally infected keratinocytes. This theory is based on the presence of dilated and congested vessels at the base of most of verrucae [18] and the mechanism of selective photother-molysis [19] that result in targeting of haemoglobin by pulsed dye laser. To our knowledge, one report used KTP laser at 532 nm wave-length for treatment of recalcitrant pigmented warts, through selec-tive photothermolysis and propagation of photoacoustic waves [20].

Nd-YAG laser hyperthermia proved to be effective in treatment of resistant warts with significant clearance of the lesions and absence of viral particles [21], but it cannot be performed on very sensitive areas for example lesions on the face, neck or cheeks. Patients will not tolerate the procedure since it is done without anaesthesia and needs laser exposure time of 1-2 min in comparison to the pulsed lasers with micro and milliseconds pulse durations. Thus laser hyper-thermia is not practical for large number of lesions.

The Nd-YAG laser is one of the most versatile and interesting lasers in dermatological laser medicine. Almost no other laser has such a wide spectrum of applications. Depending on wavelength (1064 nm) and mode (continuous, Q-switched, long pulsed), it is applied on benign pigmented, vascular lesions and permanent hair reduction [22, 23], due to the fact that 1064nm is absorbed by all the skin chro-mophores. Reports using long pulsed Nd-YAG laser as an effective line of treatment for vascular lesions such as telengietasia and venous lakes [24], encouraged us to use this laser system for thermal destruction of resistant flat warts. With its deeper penetration and lower absorption coefficient for melanin, there is less concern for col-lateral epidermal damage [25].

Unlike ablative treatment modalities, with long pulsed Nd-YAG laser therapy, no wound was created, especially if the lesions were on exposed parts of the body mostly head and neck as in our study, thus avoiding prolonged post operative pain, scarring or downtime. Applying the pulsed mode of laser system, made the technique toler-able by the patients, most of whom returned to work or normal activ-ities immediately postoperatively. There was no need for local infiltration anaesthesia (only topical anaesthetic cream was used for selected cases) was another advantage.

The limited number of sessions up to three sessions in our protocol was to be comparable to other treatment modalities such as topical retinoids, chemical cautery also for the cost benefit wise. Most of the patients who experienced partial response was due to their large number of warty lesions, most of the lesions were not de novo, they were being treated before and lasted for more than six months. The risk of high incidence of post inflammatory hyperpigmentation is minimized by preferentially sparing epidermal pigment. The proce-dure proved to be acceptable and effective by the patients. Our

A Before treatment   B Immediately after treatment   C After 2 laser treatments

Figure 1

A Before treatment   B Immediately after treatment   C After 2 laser treatments

Figure 2

A Before treatment   B Immediately after treatment   C After 2 laser treatments

Figure 3

results are comparable to pulsed dye laser treatment modalities which was another positive point, with an advantage over the pulsed dye laser of having no post laser purpura and no consumables such as dye kit.

Conclusion and Recommendations
Long Pulsed Nd-YAG laser can be added to the long list of traditional treatment of plane warts as an effective, safe and well tolerated method with minimal complications. We recommend the following inclusion criteria for long pulsed Nd-YAG laser treatment of plane warts: limited numbers of warty lesions, especially on very sensitive areas, lasted for less than six months with no previous attempt of treatment. In Patients with previous criteria, long pulsed Nd-YAG laser would be significantly more costly effective than other treat-ment modalities.

Address of Correspondence:
Dr. Ashraf Badawi Dermatology
Unit
National Institute of Laser Enhanced Sciences, Cairo University Giza, Egypt
ashrafbadawi@hotmail.com

ANKÜNDIGUNG
16. Jahrestagung der Arbeitsgemeinschaft Dermatologische Histologie „adnextumoren, Vaskuläre Tumoren, Alopezie, Teledermatohistologie

7.-9. März 2008, Friedrich-Schiller-Universität, Jena Veranstalter:
Arbeitsgemeinschaft Dermatologische Histologie (ADH) der DDG
Ansprechpartner:
Mandy Wagner, Conventus GmbH
Tel. 03641 3533222, mandy.wagner@conventus.de

Frühjahrstagung der Sächsischen Dermatologischen Gesellschaft e.V. in Zusammenarbeit mit dem Berufsverband der niedergelassenen Dermatologen e.V.

15. März 2008, Universitätsklinikum Leipzig AöR, OKL (Hörsaal) Veranstalter:
Klinik für Dermatologie, Venerologie und Allergologie in Leipzig Prof. Dr. Jan C. Simon

References
1 Cobb MW (1990) Human papillomavirus infection. J Am Acad Dermatol 22: 547-66.
2 Bunney MH, Nolan MW, Williams DA (1976) An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol 94: 667-79.
3 Gibbs RC, Scheiner AM (1978) Long-term follow-up evaluation of patients with electrosurgically treated warts. Cutis 21: 383-4.
4 Shumer SM, O Keefe EJ (1983) Bleomycin in the treatment of recalcitrant trant warts. J AM Acad Dermatol 9: 91-6.
5 Street ML, Roenigk RK (1990) Recalcitrant periungual verrucae: the role of carbon dioxide laser vaporization. J Am Acad Dermatol 23: 115-20.
6 Lim JTE, Goh CL (1992) Carbon dioxide laser treatment of periungual and subungual viral warts. Australas J Dermatol 33: 87-91.
7 Jain A, Storwick GS (1997) Effectiveness of the 585nm flashlamp pulsed tunable dye laser (PTDL) for treatment of plantar verrucae. Lasers Surg Med 21: 500-5.
8 Ross BS, Levine VJ, Nehal K, Tse Y, Ashinoff R (1999) Pulsed dye laser treatment of warts: an up date. Dermatol Surg 5: 377-80.
9 Vargas H, Hove CR, Dupree ML, William EF (2002) The treatment of facial verrucae with pulsed dye laser. Laryngoscope 9: 1573-6.
10 Kopera D (2003) Verrucae vulgares: flashlamp-pumped pulsed dye laser treatment in 134 patients. Int J Dermatol 11: 905-8.
11 Wu C, Langan S, Kilmurray M, Lawlor D, Watson R (2003) Efficacy of pulsed dye laser for viral warts- an internal audit. Ir Med J 3: 80,82-3.
12 Komericki P, Akkilic M, Kopera D (2006) Pulsed dye laser treatment of genital warts. Lasers Surg Med 38: 273-6.
13 Kilkenny M, Marks R (1996) The descriptive epidemiology of warts in the community. Australas J Dermatol 2: 80-86.
14 Brodell RT, Bredle DL (1995) The treatment of palmar and plantar warts using natural alpha interferon and needeless injector. Dermatol Surg 21: 213-8.
15 Beissert S, Koch U, Sunderkotter C, Luger TA, Schwarz T (1993) Successful treatment of diieminated verrucae vulgares with interferon beta. J Am Acad Dermatol 29: 1041-1042.
16 Yilmaz E, Alpsoy E, Basaran E (1996) Cimetidine therapy for warts; a placebo-controlled, double-blind study. J Am Acad Dermatol 34: 1005-7.
17 Serour F, Somekh E (2003) Successful treatment of recalcitrant warts. Eur J Pediatr Surg 2003 13: 219-23.
18 Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, editors (1997) Levers histopathology of the skin. 8th ed. Philadelphia^ Lippincott p. 578-82.
19 Anderson RR, Parrish JA (1983) Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 220: 524-7.
20 Li Y, Yang K (2001) Treatment of recalcitrant-pigmented flat warts using frequency doubled Q-switched Nd-YAG laser. Lasers Surg Med 29: 244-7.
21 Alxander P, Talal A, Wolfgang B, Ulrich H, Michael L (1994) Nd-YAG laser hyperthermia in the treatment of recalcitrant verrucae vulgares (Regensburgs technique). Acta Derm Venerol 74: 212-214.
22 Groot D, Rao J, Johnston P, Nakatsui T (2003) Algorithm for using a long pulsed Nd-YAG laser in the treatment of deep cutaneous vascular lesions. Dermatol Surg 29: 35-42.
23 Dierickx C (2002) Hair removal by lasers and intense pulsed light sources. Dermatologic clinics 20: 135-146.
24 Bekhor PS (2006) Long pulsed Nd-YAG laser treatment of venous lakes: report of series of 34 cases. Dermatol Surg 32: 151-4.
25 Divya R, Eric C, Nathan S, Uebelhoer D, Thomas E (2006) Laser treatment of vascular lesions. Clinics in Dermatology 24: 8-15.

Ansprechpartner:
OÄ Dr. Regina Treudler
Tel. 0341 9718690, Fax 0341 9718609
regina.treudler@medizin.uni-leipzig.de